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Abstract 
 
The aim of this thesis is to assess the ever challenging role of MRI in predicting disability 
in relapse-onset Multiple Sclerosis (MS) patients. It consists of four parts.  
In part one a brief overview of MS is given, looking at the most up-to-date knowledge on 
aetiology, pathogenesis, most common clinical presentations and the evolution in 
diagnostic process, prognosis and ever increasing treatment options for MS patients. 
Then, a brief review of the basic physics concepts and the techniques used to assess 
disability in MS is given using both conventional and non-conventional MRI. 
In part two, the relationship of T2 white matter lesion volume (T2WMLV) with long-term 
disability is assessed in a unique cohort of MS patients seen from the disease onset with a 
clinically isolated syndrome and followed up with clinical and MRI data every 5 years up 
to 20 years. 
In part three, using cross-sectional data from the same cohort of patients, the role of 
tissue specific i.e. grey matter and white matter changes in predicting disability at 20 
years is assessed, using both atrophy measurements and magnetisation transfer ratio. 
Comparisons between sub-group of MS patients and controls are also assessed. 
Furthermore, the relationship of longitudinal T2WMLV changes with atrophy 
measurements at 20 years is also explored. 
In the fourth and final part of this thesis, a summary of the main findings of this work is 
given and there is discussion on what the future holds for the role of imaging in 
predicting disability in MS. 
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INTRODUCTION AND AIMS 
 
Multiple sclerosis (MS) is the commonest cause of neurological deficit in young adults. 
Clinically isolated syndromes (CIS) such as optic neuritis, brainstem or spinal cord 
syndromes are frequently the first clinical presentation of MS. However, not all CIS 
patients convert to MS and for those who do, disability is highly variable. Numerous 
studies have been done to identify the predictors of conversion to MS, as well as 
disability. Whilst the former issue has been well addressed in a lot of studies, the second 
issue has been a rather more challenging one.  Whilst the core of diagnosis of MS has 
been proving dissemination in time and space, and clinical information is still as 
important as it has ever been, the inclusion of MRI criteria has lead to an earlier diagnosis 
of MS. With regard to disability, initial hopes for a valuable role of MRI in predicting 
disability have diminished because of the paradox between MRI and clinical disability. 
Or is this a real paradox? Are we giving up on the MRI too early? Perhaps yes. Firstly, 
disability in MS accrues slowly; hence longitudinal studies are required to fully assess the 
predictive value of the MRI. Most of the studies so far have been of a rather short to 
medium length. Extended longitudinal studies, challenging though they might be, are 
crucial not only for assessing the predictive value of MRI but also for assessment of the 
true efficacy of disease modifying therapy. Secondly, for a long-time MS was seen as a 
white matter (WM) inflammatory-demyelinating disease and as of today, still remains 
classified as a WM disease. Along with this, it was felt that inflammation and 
demyelination in WM lesions are the most important pathological processes in MS and 
neurodegeneration is a very late process in MS. However, the ever increasing evidence, 
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both from pathological and quantitive MRI studies, suggest that neither of these concepts 
holds true any longer. Not only is MS a more global disease of the CNS - with MS 
plaques in brain WM tissue being one component - where both the macroscopically 
normal appearing WM and the grey matter (GM) in addition to the spinal cord are all 
affected. Also, it is evident that neurodegeneration is a process that occurs early in 
disease course. The relationship between neurodegeneration and 
inflammation/demyelination is still unclear. However, evidence has emerged indicating 
that neurodegeneration is responsible for the irreversible disability in MS but also that it 
occurs in the GM as well as WM, where it may have an important role in long-term 
disability.  Finally, the current available disability scales in MS are heavily waited 
towards physical disability and do not take into account the full spectrum of MS effects 
including cognitive dysfunction. 
With this in mind, after an overview of the MS and MRI in MS, the work in this thesis 
looks at the role of longitudinal changes in WM lesions in predicting long-term disability 
in a rather unique cohort of patients – the longest MRI study of the CIS patients to-date - 
followed up from the disease onset every five years up to 20 years. It then further 
explores the role of the cross-sectional tissue specific abnormalities as measured by GM 
and WM volume and GM and WM magnetisation transfer ratio in addition to the WM 
lesion volume at 20 years in predicting long-term disability. Finally, it assesses the 
relationship between the longitudinal changes of WM lesions with tissues specific brain 
volumes at 20 years. 
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PART I 
 
INTRODUCTION 
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Chapter I 
 
Multiple Sclerosis 
 
 
 
1.1 Introduction  
 
Multiple sclerosis (MS), the commonest cause of non-traumatic neurological disability in 
young adults in Europe and North America, is a chronic autoimmune disease of the 
central nervous system which affects both the white and grey matter (WM and GM). 
Worldwide it affects nearly 2.5 million individuals (Noseworthy et al., 2000; 
Weinshenker, 1996). In United Kingdom about 100-200/100,000 people have MS with an 
incidence of about 7/100,000 of new cases diagnosed with MS each year and a lifetime 
prevalence of 2/1000 (MacDonald et al., 2000). Worldwide, however, there is a marked 
geographical variation in prevalence (Compston, 1999) with the incidence of MS 
reported to be increasing (Gray et al., 2008; Orton et al., 2006). MS usually starts 
between 20 - 40 years of age and onset is rare after 60 years of age. Although MS occurs 
in childhood accounting for less than  5% of all MS cases, it is rare before 10-years of 
age (Renoux et al., 2008). Like other autoimmune diseases, MS has a female 
predominance with a sex ratio (female/male)  of 2:1 although, recently in some regions 
increase in the incidence of MS in women is shown, to a ratio of more than 3:1 (Orton et 
al., 2006). In progressive forms of MS the clinical disease onset occurs later than in 
relapsing-remitting forms and the incidence is similar in males and females (Cottrell et 
al., 1999; Thompson et al., 1997). 
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1.2 Aetiology 
Currently there is little evidence for a single cause of MS, although the evidence so far 
supports the hypothesis that a combination of infectious and environmental causes on a 
background of a genetic susceptibility are relevant aetiological factors. 
 
Genetics 
It is evident that MS is not a “pure” genetic disease i.e. not transmitted by Mendelian 
inheritance. Nevertheless, there is evidence from several sources that there is a genetic 
predisposition to developing MS. It is believed that MS is triggered by environmental 
factors (see later) in individuals with rather complex genetic-risk profile (Compston & 
Coles, 2008).  
MS is more common in white people especially those of Northern European descent than 
in non-white ethnic groups and is very rare in some regions. Also the differences in the 
distribution of MS within the same region, such as United Kingdom for example, where 
the frequency of MS is higher in the northern than southern part, (highest in Scotland), 
may reflect differences in the genetic characteristics of the population at risk (Compston 
A, 2005). Furthermore, studies of twins and siblings suggest that the genetic factors 
influence the susceptibility to MS with evidence suggesting that multiple genes, each 
exerting only a modest effect, probably play a role (Hafler et al., 2007; Islam et al., 
2006).  
Several candidate genes have been identified as genetic risk factors for susceptibility to 
MS. Variation in major histocompatibility complex  (MHC) on chromosome 6p21 is 
known to influence susceptibility to MS with the strongest genetic effect coming from 
  
 
26
one of the most validated ones, human leukocyte antigen (HLA) DRB1*1501 haplotype 
(DR15) in the class 2 region (Lincoln et al., 2005; Yeo et al., 2007). But non-HLA genes 
have also been identified, more recent ones being interleukin 7 and 2 receptor alpha chain 
(IL7RA and IL2RA) (Hafler et al., 2007; Lundmark et al., 2007; Weber et al., 2008). 
 
But despite the strong genetic link and clustering of MS in families the concordance rate 
between monozygotic twins is below 30%. While MS has a familial recurrence rate of 
about 20%, (siblings 5%; parents 2% and children 2%) the reduction in risk changes from 
3% in first degree relatives to 1% in second and third degree relatives (Compston & 
Coles, 2008). 
Although there appears to be a genetic influence in predisposing one to develop MS, 
some believe that the disease manifests only when environmental factors are triggered. 
The studies done on immigrants support this argument. Overall the migration studies 
emphasize MS as an exogenous disorder, acquired some years before clinical expression 
and probably in childhood, whereas studies of indigenous peoples provide more 
compelling evidence for genetic effects on disease frequency and distribution (Compston 
A, 2005).  Migration studies have shown alteration in the risk of MS - depending on age 
of migration – of people moving from areas of high risk to those of low risk and vice-
versa, supporting the hypothesis of environmental factors modifying the inherent risks of 
MS dependant on ethnicity, although it becomes important to establish when these 
influences occur (Compston A, 2005; Dean & Elian, 1997; Elian & Dean, 1987).  
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Environmental causes 
Although genetic susceptibility explains the clustering of  MS cases within families and 
the sharp decline in risk with increasing genetic distance, it can not fully explain the 
geographic variations in MS frequency and the changes in risk that occur with migration 
which can be explained perhaps by the influence of environmental factors (Ascherio & 
Munger, 2007b).  
 
a) Infectious 
Many viruses and bacteria have been suspected of causing MS. So far, there is no human 
study that will definitely establish or dismiss the role of infections in MS. One of the 
infectious causes which have been thought to cause MS is Epstein Barr virus (EBV) -  
which also causes infectious mononucleosis - and more recently human herpes virus-6 
(HHV-6) (Moore & Wolfson, 2002). Some studies have suggested that developing the 
infection at a critical period of exposure may lead to conditions conducive to the 
development of MS a decade later. Although EBV is a ubiquitous B-lymphotropic herpes 
virus that infects around 90% of the adult population worldwide, studies have shown that 
the risk of developing MS is higher in those with previous history of infectious 
mononucleosis and it is extremely low in those who are EBV seronegative (Ascherio & 
Munger, 2007a; Thacker et al., 2006). A recent study looking at the post-mortem brain 
specimen of people with MS has shown that nearly 100% of them (21 of 22) had been 
infected with EBV (Serafini et al., 2007). Whilst more and bigger studies are needed to 
replicate these results, this recent study has re-opened the enthusiasm that the early 
studies showed on being close on identifying the cause of MS.  
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Some believe that the “epidemics” of MS, such as the ones in the Faroe Islands further 
support the role of environment in the pathogenesis of MS although others believe that 
this is more likely representative of the increasing recognition of MS (Benedikz et al., 
1994). Despite EBV standing out as perhaps the only infectious agent that can explain 
many of the key features of MS epidemiology, the link between EBV and MS cannot 
explain the decline in risk among migrants from high to low MS prevalence areas 
(Ascherio & Munger, 2007a). 
 
b) Non-infectious 
Findings from studies on seasonality in MS patients’birth, disease onset and 
exacerbations, as well as apparent temporal trends in incidence and gender ratio support 
an influential effect of viruses, metabolic and lifestyle factors on MS risk, vitamin D 
status, and smoking, in addition to EBV, as factors that may partly explain these 
epidemiological patterns (Pugliatti et al., 2008).  
 
There is a geographical variation in the incidence of MS in the world. MS is more 
prevalent in countries with temperate climate including Northern Europe, Southern 
Canada, Northern United States, South-eastern Australia and New Zealand. It is this 
striking prevalence of MS that increases with latitude which has made vitamin D 
deficiency a possible pathogenic co-factor in MS (Handunnetthi et al., 2010; Lucas et al., 
2011). A recent study has shown that high levels of 25-hydroxyvitamin D was associated 
with lower incidence of MS and MS-related disability only in women (Kragt et al., 2009). 
Whilst the evidence of involvement of vitamin D in pathogenesis of MS can not be 
ignored, it is far from clear. 
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Smoking has emerged as a potential factor in the pathogenesis of MS, and although the 
studies so far do not prove a cause-and effect relation, some suggest that smoking is not 
only associated with an increase risk of MS (Hernan et al., 2001), but it may also be a 
risk factor for transforming a relapsing-remitting clinical course to secondary -
progressive phase (Hernan et al., 2005). There is suggestion that the differences in 
smoking habits across the populations could perhaps explain some of the variation in MS 
incidence, such as the increase in female/male sex ratio in Canada over the past 50 years 
(Ascherio & Munger, 2007b; Orton et al., 2006). The role of other environmental factors 
as either protective or risk factors in MS is less well established (Ascherio & Munger, 
2007b). 
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1.3 Pathogenesis 
The pathology of MS was originally defined as an inflammatory process, associated with 
focal plaques of primary demyelination in the WM of the brain and spinal cord (Charcot 
1880). Since that first description a lot has changed in our understanding of the pathology 
in MS. We now know that MS is not exclusively a WM disease and that there is more to 
MS than just inflammation and demyelination; the pathological spectrum is much wider. 
Axonal loss and damage are important processes in the pathogenesis of MS and seem to 
appear more clinically relevant. Whilst there is generally an agreement on the 
pathological processes occurring in MS i.e. inflammation, demyelination, remyelination 
and neurodegeneration, there is less agreement on the timing and the order of events and 
the mechanisms leading to these pathological processes.  
 
On one hand, there are those who believe that MS remains primarily a chronic 
inflammatory demyelinating disease of the central nervous system involving both brain 
and the spinal cord in which focal lymphocytic infiltration leads to damage of myelin and 
axons. Initially this process is transitory leading to remyelination which clinically is 
manifested by the recovery of neurological dysfunction. Over time the pathological 
changes become dominated by widespread microglial activation associated with chronic 
neurodegeneration and clinically manifested by the progressive accumulation of the 
disability (Compston & Coles, 2008).  And whilst there is extensive injury of the so-
called normal-appearing WM (NAWM) tissue and GM involving both the cortex and the 
deep GM, with extensive demyelination and axonal damage, it is believed that this 
neurodegenerative component does not develop independently of the inflammation  and 
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the inflammation is the driving force of both demyelination and neurodegeneration in MS 
(Lassmann et al., 2007). 
 
On the other hand there are those who challenge this concept. There is increasing 
evidence from pathological and Magnetic Resonance Imaging (MRI) studies that the 
axonal pathology such as axonal transections or acute axonal damage occurs early not 
only in MS lesions, but also in NAWM. Furthermore the cortical pathology - 
demyelination and neuroaxonal damage - also appears to be an early event in lesion 
pathogenesis and contribute to permanent clinical disability. All these findings show not 
only neurodegeneration being an important component of the pathology of MS but also 
some believe, it provides evidence for a primary neurodegenerative event in the 
pathogenesis of MS lesions. The presence of diffuse NAWM injury, marked GM 
involvement and significant cortical functional reorganizational as well as 
neurodegeneration - which is only partially linked to demyelination, from the early onset 
of the disease, has laid to the concept of MS as a “two-stage” disease (i.e. early 
inflammation followed by late neurodegeneration) to be replaced by the concept of  
“simultaneous two-component” disease where both processes occur simultaneously 
(Charil & Filippi, 2007; Hauser & Oksenberg, 2006). Some have even raised questions 
whether MS could still be considered an autoimmune disease or is indeed a primarily 
neurodegenerative disease with secondary inflammatory demyelination (Trapp & Nave, 
2008). 
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Immunology 
Although the immunological processes in MS are complex and not fully understood, the 
mainstream view is that MS is caused by an autoimmune attack of the central nervous 
system (CNS) myelin by myelin-specific CD4 T cells (McLaughlin & Wucherpfennig, 
2008). There is considerable evidence that auto-reactive T cells proliferate, cross the 
blood-brain barrier and enter the CNS under the influence of cellular adhesion molecules 
and pro-inflammatory cytokines. However other cell populations of the immune system 
are also involved in the complex series of events leading to the development of MS. B 
cells contribute to the pathogenesis of MS, through their role as antigen-presenting cells 
to T cells with matching antigen specificity, the production of pro-inflammatory 
cytokines and chemokines, and the secretion of auto-antibodies that target structures on 
the myelin sheath and the axon (McLaughlin & Wucherpfennig, 2008). 
The genetic linkage with HLA class II alleles (DRB1*1501, DRB1*0101 and 
DQB1*0602) and specific alleles of the IL2 and IL7 receptors (also implicated in the 
pathogenesis of other autoimmune diseases such as type 1 diabetes and Grave’s disease) 
and involvement of auto-reactive T and B cells support the auto-immune hypothesis. 
These results add to the pathological and immunological studies in suggesting that MS is 
an autoimmune inflammatory disorder (Compston & Coles, 2008).  
 
WM lesions  
The pathological hallmark of MS is the formation of the sclerotic plaques which 
represents the end stage of a process involving inflammation, demyelination, 
remyelination, oligodendrocyte depletion and astrocytosis and neuronal and axon 
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degeneration. Inflammatory infiltrates are typified by the presence of both CD4+ 
(helper/inducer) and CD8+ (cytotoxic/suppressor) cells but lower numbers of other 
mononuclear cells (B cells and macrophages/microglial cells) are also consistently found. 
Lesions are typically sharply demarcated, usually oval or round in shape, often centred 
around venules [one or several medium sized blood vessels (Lassmann et al., 1998)]. 
They vary in appearance, size (from less than one millimetre to several centimetres), age 
(acute or chronic) and although they can be distributed throughout the CNS, their typical 
sites include: optic nerve, corpus callosum, infratentorial, periventricular and spinal cord 
– mainly cervical region, as well as GM (see later).  
Several attempts have been made to classify the lesions (Lassmann et al., 1998; van, V & 
De Groot, 2000). More recently Lucchinetti et al have proposed a classification of active 
lesions in four patterns based on the distribution of myelin loss, the plaque geography and 
extension, the pattern of oligodendrocyte destruction, and immunoglobulin and 
complement deposition (Lucchinetti et al., 2000). The authors conclude that this proves 
the heterogeneity of the MS lesions and further suggest that any single patient has only 
one of these four patterns. It is important to mention that in this study, much of the 
material was somewhat unusual – a high percentage of biopsy material, hence not a 
typical MS presentation and many of the lesions were acute, hence not covering the full 
spectrum of lesion formation/development. Whilst we still wait for other studies to 
confirm these findings, they have been challenged by a more recent pathological study 
performed in a relapsing-remitting MS (RRMS) patient who died either during or shortly 
after an acute relapse, which showed that in the very early stages of lesion formation, 
extensive oligodendrocyte apoptosis and microglial activation in myelinated tissue 
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occurred at sites devoid of T-cell or B-cell infiltrates, although there was inflammation in 
the regions adjacent to the active lesion (Barnett & Prineas, 2004). These findings and the 
spectrum of pathological changes in nearby or distant phagocytic plaques suggest, the 
authors conclude, that the pathological heterogeneity in MS is largely due to evolution of 
lesional pathology, rather than true pathogenic heterogeneity (Barnett et al., 2006).  
 
It is well established that the axonal loss and injury occurs at an early stage in WM 
lesions, it is related to the degree of inflammation within lesions and it is considered to be 
a correlate of the irreversible disability in MS (Trapp et al., 1998).  
 
 
Normal Appearing White Matter 
 
Neuropathological studies of the macroscopically NAWM has revealed clear 
abnormalities: diffuse tissue injury such as astrogliosis, microglial activation, patchy 
demyelination and peri-vascular inflammation as well as evidence of axonal loss which 
seem to be, at least partially, independent of focal inflammatory demyelinating plaques 
(DeLuca et al., 2006; Evangelou et al., 2000). Whilst changes in the NAWM are seen at 
all stages of  MS, these are more severe in more disabled patients (Kutzelnigg et al., 
2005). They vary from diffuse inflammation (Kutzelnigg et al., 2005) to progressive 
axonal loss (Bjartmar et al., 2001; Evangelou et al., 2000). However, the axonal loss is an 
early event not only in lesion formation but also in NAWM (Bjartmar et al., 2001; 
Evangelou et al., 2000). Whilst the mechanisms of injury in NAWM remains still unclear 
the knowledge gained from the MRI studies suggest the perhaps that there is a component 
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due to Wallerian degeneration in NAWM secondary to the axonal transections associated 
with the inflammatory demyelination within lesions (Narayanan et al., 2006).  
 
Grey Matter 
There is now mounting evidence of GM involvement in MS. But despite the knowledge 
of the presence of GM lesions since early on (Brownell & Hughes, 1962), the assessment 
of GM pathology and its role in disability in MS has been rather slow until quite recently. 
This is perhaps due, at least partially, to the difficulties of visualising the GM lesions 
with current histo-chemical staining for myelin as well as with conventional MRI; the 
histology still revealing more cortical plaques than MRI (Geurts et al., 2008; Geurts & 
Barkhof, 2008; Kidd et al., 1999).  
Cortical lesions are common in MS and are observed in about 90% of autopsy cases with 
chronic MS (subpial > leucocortical [i.e. involving cortex as well as juxtacortical WM] > 
purely intracortical) (Wegner et al., 2006). Cortical demyelination is more extensive in 
patients with progressive disease and can occur in the near absence of focal WM lesions 
(Bo et al., 2007; Kutzelnigg et al., 2005; Kutzelnigg et al., 2007). GM lesions differ from 
WM lesions: they are less inflammatory and rather more destructive (Bo et al., 2003; Bo 
et al., 2007; Peterson et al., 2001; Trapp & Nave, 2008). Axonal transections and 
neuronal apoptosis in cortical lesions (Peterson et al., 2001), reduction of glia, neurons 
and synapses in leucocortical lesions (Wegner et al., 2006), decrease of Purkinje cells in 
cerebellar cortical lesions (Kutzelnigg et al., 2007) and extensive involvement of the GM 
in brain and spinal cord (Gilmore et al., 2008), all provide evidence of extensive GM 
lesions with features of neurodegeneration. Whilst inflammation can lead to axonal loss 
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(Trapp et al., 1998), the axonal damage of the GM seems to be largely independent of 
WM lesions. The mechanisms of GM damage are still not fully understood but several 
mediators of axonal damage have been identified such as CD8 cytotoxic T-cells, 
macrophages/microglia, cytokines (nitric oxide) and glutamate. 
Whilst not much data is available on the pathology, if any, of the non-lesional GM it is 
believed that the main contribution of the GM pathology to disease progression is 
through GM lesions. In addition, cortical reorganization may be important in the 
limitation of functional impairment. Recent functional MRI studies suggest that cortical 
adaptation in MS patients may help to limit functional impairment (Rocca et al., 2005; 
Rocca et al., 2010). It is plausible that extensive cortical disease especially in secondary-
progressive MS (SPMS) leads to limited cortical plasticity with severe functional 
consequences .   
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1.4 Clinical manifestations and natural history  
In about 85% of cases the disease starts with an acute episode of neurological deficit 
known as clinically isolated syndrome (CIS). The most common sites affected are optic 
nerve, brainstem or spinal cord although other presentations in other locations (and some 
times multifocal) are recognised. MS affects the whole CNS and other presentations, as 
well as the above mentioned, such as cognitive and psychiatric symptoms, are also 
recognised. Whilst most of the above mentioned are not specific to MS, Lhermitte’s 
symptom – paraesthesia  of the trunk and limbs on neck flexion and Utoff’s phenomenon 
– blurred vision with increasing body temperature such as after a hot bath or exercise, are 
relatively specific to MS. 
 
Whilst most of those who present with a CIS convert to MS [as high as 80%  (Eriksson et 
al., 2003)], not all of them do (Brex et al., 2002; O'Riordan et al., 1998c). Optic neuritis 
(ON) is the most studied CIS perhaps due to the fact that it is the most distinctive and 
homogenous of the CIS syndromes and because its clinical presentation is more specific 
for demyelination than symptoms of brainstem or spinal cord that are more 
heterogeneous and have a rather wider differential diagnosis.  Of those who present with 
a CIS, bilateral simultaneous ON and complete transverse myelitis (Lipton & Teasdall, 
1973) have a much lower rate of converting to MS. Whilst the incidence of ON is fairly 
constant, its association with MS varies [frequent in United Kingdom (Swanton et al., 
2006) and infrequent in Japan]. Those studies that have included brainstem and spinal 
cord syndrome patients in addition to ON patients have reported a similar conversion rate 
to MS amongst all syndrome presentations (Barkhof et al., 1997; Lee et al., 1991; 
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O'Riordan et al., 1998c; Tintore et al., 2000). Although a more recent study has shown 
that the conversion rate of ON versus non-ON CIS, is lower (Tintore et al., 2005), the 
conversion rate was similar across different CIS presentations when only patients 
presenting with ON and with an  abnormal baseline brain MRI were included. (The role 
of MRI in predicting conversion to MS will be discussed in Chapter 3). 
 
Most CIS patients who convert to MS will enter a relapsing-remitting course and the 
majority of them will then progress to the secondary-progressive stage, but the time and 
the course of this progression varies widely. A minority of CIS patients who convert to 
MS, can enter the progressive stage after a single relapse. An International panel defined 
the MS course in 1996 (Lublin & Reingold, 1996) (Table 1.1). Relapses are defined as 
the first occurrence, recurrence or worsening of symptoms of neurological dysfunction 
marked by sub-acute onset and a period of stability followed by either partial or complete 
recovery – the whole process lasting more than 24 hours. Progression is defined as steady 
worsening of at least more than 6 months. 
In ~15% of cases, clinical progression with or without superimposed relapses [primary 
progressive MS (PPMS)] is seen from the disease onset (Cottrell et al., 1999; Thompson 
et al., 1997). Whilst there is sometimes discussion whether PPMS and relapse-onset MS 
are two different entities, most believe that they represent a spectrum of the same 
disorder.  
 
The level of disability and the disease progression in MS is most often assessed by 
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) consist of scoring eight 
functional systems namely:  visual, brainstem, pyramidal, cerebellar, sensory, bowel and 
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bladder and cerebral function. It ranges from 0 to 10 with 0 meaning no evidence of 
disability and 10 meaning death due to MS (Table 1.3). The EDSS scores above 4 are 
mainly driven by ambulation. In clinical trials other disability measurement such as MS 
Functional Composite Score (MSFC), which takes into account the upper limb function 
and cognitive impairment of the MS patients, has also been widely used (Cutter et al., 
1999; Fischer et al., 1999). 
 
 
Prognosis   
As mentioned earlier, whilst most (~65%) RRMS patients go on to develop SPMS, the 
rate of progression varies widely. The progressive stage typically starts for both forms 
(SPMS and PPMS) around 40 years of age (Confavreux & Vukusic, 2006). From natural 
history studies, several factors have been identified as good prognostic factors in relapse 
onset MS (first presentation with ON, mono-focal presentation or sensory symptoms; 
being female; younger age of disease onset; lengthy time between the first to the next 
episode; low relapse rate on the first 2 years; minimal disability after 5 years) 
(Confavreux et al., 2003; Eriksson et al., 2003; Kurtzke et al., 1977; Miller et al., 1992; 
Nilsson et al., 2005) and several others as bad prognostic factors (being male; older age 
of disease onset; multifocal disease onset; high relapse rate in the first 2-5 years; 
substantial disability after 5 years) (Eriksson et al., 2003; Miller et al., 2005; Scalfari et 
al., 2010; Weinshenker et al., 1989). The role of MRI prognostic factors will be discussed 
in detail in Chapter 3.  
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The reported time to EDSS 6 (i.e. requiring assistance to walk) varies from 15 years 
(Canadian and Swedish series) (Kremenchutzky et al., 2006; Weinshenker et al., 1989) to 
23 years (French series) (Confavreux et al., 2000). It might be possible that the outcome 
in MS differ with geography (Ebers & Daumer, 2008). Not all patients develop severe 
disability and some with little disability after many years are known as benign MS 
(BMS). 
 
The definition of BMS is based on disease duration of at least 15 years, and an EDSS ≤ 3 
(Lublin & Reingold, 1996). Although in some population based studies, a high 
percentage of people with BMS have been identified who have remained stable with 
follow-up (Pittock et al., 2004), other studies have shown that the term BMS is rather 
temporary, as  many of these patients go on to develop more disability if they are 
followed on for long enough (Hawkins & McDonnell, 1999; Hirst et al., 2008; Sayao et 
al., 2007). New definitions of BMS have been introduced such as lowering of the EDSS 
score to <=2 although some other authors suggest that it would be best to use an index of 
progression rather than an arbitrary disease duration and EDSS cut-off (Weinshenker et 
al., 1989). 
 
Death is attributed to MS in two-third of cases and to increased risk and complications of 
infections such as skin, pulmonary and urinary infections. The median time to death is 30 
years from the disease onset, representing a reduction in life expectancy of 5-10 years. 
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Table 1.1  Lublin & Reingold (1996) definitions of clinical course of multiple sclerosis 
(Lublin & Reingold, 1996) 
 
Clinical 
course 
Definition 
RRMS Clearly defined disease relapses with full recovery or with sequelae and 
residual deficit upon recovery; periods between disease relapses 
characterised by a lack of disease progression. 
SPMS Initially RR disease course followed by progression with or without 
occasional relapses, minor remissions, and plateaus. 
PPMS Disease progression from onset with occasional plateaus and temporary 
minor improvements allowed. 
PRMS Progressive disease onset, with clear acute relapses, with or without full 
recovery; periods between relapses characterised  by  continuing 
progression 
 
 
RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple 
sclerosis; PPMS = primary progressive multiple sclerosis; PRMS = progressive-relapsing 
multiple sclerosis 
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Table 1.2  Kurtzke’s Expanded Disability Status Scale (EDSS) (Kurtzke, 1983). 
 
 
EDSS 
score 
Definition 
0 Normal neurological examination (all FS normal, mild cerebellar sign acceptable 
1.0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 Minimal disability in two FS 
3.0 Moderate disability in one or mild disability in up to four FS though fully ambulatory 
3.5 Fully ambulatory but with a moderate disability in one FS and mild disability in one 
or two others; or moderate disability in two FS; or mild disability in five FS 
4.0 Fully ambulatory without aid; self-sufficient; up and about some 12 hours a day 
despite relatively severe disability in one FS or combinations of exceeding the limits 
of previous step. Able to walk without aid or rest for 500m. 
4.5 Fully ambulatory without aid; up and about much of the day; may otherwise have 
some limitation of full activity or require minimal assistance. Able to walk without 
aid or rest for 300m. 
5.0 Ambulatory without aid or rest for 200m; disability severe enough to impair full 
daily activities. 
5.5 Ambulatory without aid or rest for 100m; disability severe enough to impair full 
daily activities. 
6.0 Intermittent or unilateral constant assistance required to walk 100m. 
6.5 Constant bilateral assistance to walk 20m without rest. 
7.0 Unable to walk 5m even with aid. Essentially restricted to a wheelchair. Transfers 
alone. 
7.5 Unable to walk more than few steps. May need aid with transfers. 
8.0 Restricted to bed or chair or perambulated in wheelchair. Generally has effective use 
of arms. Out of bed for much of the day 
8.5 Essentially restricted to bed for much of the day. Retains some self-care functions 
9.0 Helpless bed patient; can communicate and eat 
9.5 Totally helpless, unable to communicate effectively or eat/swallow 
10.0 Death due to MS 
 
FS = Functional system 
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1.5 Diagnosis 
To make a diagnosis of MS, dissemination in time and space is required. And whilst over 
the years several diagnostic criteria have been designed, the most commonly used are the 
Poser criteria (Poser et al., 1983) (Table 1.3) and the most recent criteria of the 
International Panel on the Diagnosis of  Multiple Sclerosis (McDonald et al., 2001; 
Polman et al., 2005) (Polman et al., 2011) (Table 1.4 and 1.5).  These sets of criteria 
emphasise the importance of history taking and clinical examination in establishing the 
dissemination in space and time (DIS and DIT) which remains the core of the diagnosis 
of MS. The emergence of new disease modifying drugs (DMDs) and their role in 
delaying the conversion to MS has lead to a need for a quicker and safer diagnosis of MS. 
Another reason for updating the criteria is the fact that MRI often shows silent lesions 
characteristic for MS in people with CIS and that such lesions influence the risk for MS. 
Whilst one can not make the diagnosis of MS on MRI findings only, the inclusion of the 
MRI criteria has proved to be the most sensitive paraclinical tool in establishing DIS and 
DIT at an earlier stage in the clinically manifested disease. MRI is also important in 
exclusion of conditions that are clinically similar to MS (Charil et al., 2006; Miller et al., 
2008). 
 
Other important paraclinical tools used are visual evoked potentials, and oligoclonal 
bands (IgG) in the CSF, the local synthesis of which can be detected in about 95% of MS 
patients (Andersson et al., 1994).  
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In the work presented in this thesis, clinical Poser criteria only, were used to define 
clinically definite MS: i.e. a second clinical episode with objective new neurological 
signs was used as a clear evidence for DIS and DIT (CDMS A1).  
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Table 1.3  Poser’s MS diagnostic criteria (Poser et al., 1983) 
 
Category Attacks Clinical 
evidence 
 Para-clinical 
evidence 
CSF (oligoclonal band or 
increased IgG index) 
A Clinically definite MS (CDMS) 
CDMS 
A1 
2 2    
CDMS 
A2 
2 1 and 1  
B Laboratory-supported definite MS (LSDMS) 
LSDMS 
B1 
2 1 or 1 +  
LSDMS 
B2 
1 2   + 
LSDMS 
B3 
1 1 and 1 + 
C Clinically probable MS (CPMS) 
CPMS C1 2 1    
CPMS C2 1 2    
CPMS C3 1 1 and 1  
D Laboratory-supported probable MS (LSPMS) 
LSPMS 2    + 
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Table 1.4  International Panel on the Diagnosis of MS criteria (Polman et al., 2005) 
 
Clinical presentation Additional data needed for MS diagnosis 
Two or more attacks; objective clinical  
evidence of two or more lesions  
None 
Two or more attacks; objective clinical  
evidence of one lesion 
DIS demonstrated by:  
1. MRIa or  
2. Two or more MRI-detected lesions 
consistent with MS plus +ve CSFb 
or 
3. Await further clinical attack 
implicating a different site  
One attack; objective clinical evidence of 
two or more lesions 
DIT demonstrated by: 
1. MRIc or  
2. Second clinical attack 
One attack; objective clinical evidence of 
one lesion (mono-symptomatic 
presentation; CIS) 
DIS demonstrated by: 
1. MRIa or  
2. Two or more MRI-detected lesions 
consistent with MS plus +ve CSF 
and 
DIT demonstrated by: 
1. MRIc or  
2. Second clinical attack 
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Insidious neurological progression 
suggestive of MS 
One year of disease progression 
(retrospectively or prospectively) and  
Two of the following: 
a) Positive brain MRI (nine T2 lesions 
or four or more T2 lesions with +ve 
VEP) 
b) Positive spinal cord MRI (two focal 
T2 lesions) 
c) +ve CSF 
 
DIS = Dissemination in space; DIT = Dissemination in time; CIS = Clinically isolated 
syndrome; CSF = Cerbrospinal fluid; VEP = Visual-evoked potential 
aMRI DIS must fulfil the following criteria: ≥ 3 of the following:  
9 T2 lesions or 1 Gd-enhancing lesion; 
≥ 3 periventricular lesions; 
≥ 1 juxtacortical lesion 
≥ 1 infratentorial lesion 
A spinal cord lesion can replace an infra-tentorial lesion 
Any number of a spinal cord lesion can be included in total lesion count 
bPositive CSF determined by iso-electric focusing evidence of oligoclonal IgG bands not 
present in serum or increased IgG index or both 
cMRI DIT must fulfil the following criteria:  
A Gd-enhancing lesion ≥ 3 months after CIS onset or a new T2 lesion with reference to a 
baseline scan obtained ≥ 30 days after CIS onset 
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Table 1.5   The 2010 McDonal Criteria for Diagnosis of MS (Polman et al., 2011). 
 
Clinical presentation Additional data needed for MS diagnosis 
≥ 2 attacks; objective clinical  
evidence of ≥ 2 lesions or 
objective clinical evidence of 
1 lesion with reasonable 
historical evidence of a prior 
attack 
None 
≥ 2 attacks; objective clinical  
evidence of 1 lesion 
DIS demonstrated by:  
≥1 T2 lesion in at least 2 of 4 MS-typical regions of CNS 
(PV; JC; IT or SC) or await a further attack implicating 
a different CNS site. 
1 attack; objective clinical 
evidence of ≥ 2 lesions 
DIT demonstrated by: 
Simultanious presence of asymptomatic Gd-enhancing 
and non-enhancing lesions at any time; or a new T2 
and/or Gd-enhancing lesion (s) on follow up MRI, 
irrespective of its timing with reference to a baseline 
scan; or await a second clinical attack. 
1 attack; objective clinical 
evidence of one lesion (CIS) 
DIS demonstrated by:  
≥1 T2 lesion in at least 2 of 4 MS-typical regions of the 
CNS (PV; JC; IT or SC) or await a further attack 
implicating a different CNS site; and  
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DIT demonstrated by: 
Simultanious presence of asymptomatic Gd-enhancing 
and non-enhancing lesions at any time; or a new T2 
and/or Gd-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline 
scan; or await a second clinical attack. 
Insidious neurological 
progression suggestive of MS 
(PPMS) 
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the following 
criteria: 
1. Evidence for DIS in the brain based on ≥1 T2 
lesions in the MS-characteristic (PV, JC or IT) 
regions. 
2. Evidence for DIS in the SC based on ≥2 T2 
lesions in the cord. 
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index) 
 
MS = multiple sclerosis; CIS = clinically isolated syndrome; DIS = dissemination in 
space; DIT = Dissemination in time; PV = periventricular; JC = Juxtacortical; IT = 
infratentorial; SC = spinal cord 
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1.6 Treatment and management 
Despite the emergence of new disease modifying drugs (DMDs), there is no cure for MS 
as yet. The use of disease modifying treatment in high risk CIS patients have shown that  
the conversion to MS can be delayed, but not prevented (Beck et al., 2002; Comi et al., 
2001; Comi et al., 2009; Kappos et al., 2007). The licensed DMDs,  for use in RRMS, 
such as β-interferon (β-INF) component (1a – Avonex; Rebif and 1b - Betaferon) and 
Glatimer acetate (Copaxone), have a role in reducing the number of relapses and their 
severity by a third, but they have either little or no effect on the disease progression 
(Comi et al., 2001; Comi et al., 2009; Ebers et al., 2010; Jacobs et al., 2000a; Kappos et 
al., 2007; Kappos et al., 2006b). There are other approved DMDs such as Natalizumab 
(Miller et al., 2003; Polman et al., 2006; Rudick et al., 2006b) and Mitoxantrone (Edan et 
al., 1997) which are only used for patients with very active relapsing disease. 
Mitoxantrone, an unlicensed immunosuppressive treatment, is shown to reduce the rate of 
relapses and slow the progression of disability in active RRMS patients (Bastianello et 
al., 1994; Edan et al., 1997; Millefiorini et al., 1997) compared to those who received 
placebo or methylprednisolone. Natalizumab, a more recently licensed drug on treatment 
of MS, has shown to significantly reduce the relapse rate  by two-third and progression of 
sustained disability by ~ 40% in RRMS patients when compared to placebo (Miller et al., 
2007; Polman et al., 2006).  
Fingolimod, the first oral therapy licenced for treatment in RRMS, is without a doubt an 
exiting news for the MS community. Fingolimod is the first of a new class of drugs that 
inhibits immune cell migration by integreating with sphingosine-1-phosphate receptor. 
When compared to placebo it showed significant reduction of relapses as well as of 
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disease progression (Kappos et al., 2010) and it has shown superiority when compared to 
β-INF-1a (Cohen et al., 2010). 
 
A lot of research is still on-going to find new DMDs. More recently a randomised blinded 
trial comparing Alemtuzumab, also known as Campath-1H, a humanized monoclonal 
antibody which target CD52 lymphocytes and monocytes, with β-INF, Rebif, reduced the 
disease activity and  the rate of relapses by 74% and more importantly reduced the risk of 
sustained accumulation of disability by 71%, efficacy which was maintained at 36 
months despite the fact that nearly 72% of Alemtuzumab treated patients did not receive 
the month 24 cycle of therapy because of  safety concerns (Coles et al., 2008). There are 
also several emerging oral therapies which in preliminary trials have shown to reduce 
MRI lesion activity  +/- relapse rate (Comi et al., 2008; Giovannoni et al., 2010; Kappos 
et al., 2006b; Kappos et al., 2008; O'Connor et al., 2006). 
 
Unfortunately none of the DMD’s is free of adverse effects. Whilst the β-INF group of 
drugs cause flu-like syndromes, abnormal blood test the most serious adverse side effect 
is the occurrence of neutralizing antibodies (Nabs) and whilst the debate still continues 
there is increasing evidence  that their occurrence reduces the efficacy of the DMDs. And 
whilst there is not very much difference amongst the β-INF treatments with regard to 
their efficacy, people taking Avonex tend to have a lower rate of Nabs than the rest.  
The adverse effects with the monoclonal antibodies are much more serious. Natalizumab 
causes a life threatening illness – progressive multifocal leukoencephalopathy known as 
PML – in about 1/500-1/1000 (Clifford et al., 2010; Yousry et al., 2006), whilst 
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Alemtuzumab causes autoimmune complications such as dysthyroid disease and immune 
thrombocytopenic purpura. Also, Mitroxantrone is known to cause acute leukemia and 
cardiotoxicity (each ~1%) and hence its use is limited to highly active cases. The most 
recently oral therapy, Fingolimod, can also cause bradycardia and arterioventricular block 
as well as herpesvirus infections. So certainly one of the challenging issues for the 
neurologists treating MS patients is developing tools and strategies to optimise the risk-
benefit ratio of ever growing treatment options for RRMS patients. 
 
Whilst the above mentioned medications are used to treat acute relapsing MS, so far, no 
drugs have been shown to work on the progressive forms of MS. Experimental trials in 
progressive MS are currently focused mainly in neuroprotective strategies (Kapoor et al., 
2010). 
 
The rest of the treatment of MS is rather symptomatic looking at treating symptoms such 
as spasticity, bladder symptoms and fatigue. There is a role of high dose, short course 
corticosteroids in MS during an acute relapse, where they can hasten the recovery but do 
not influence the final outcome (Beck et al., 1992). A multidisciplinary approach with 
physiotherapy, occupational therapy, speech and language therapy and neuro-
rehabilitation, all integrated, is very important in management of MS patients especially 
when they are accumulating significant disability (Freeman et al., 1997; Thompson et al., 
2010). 
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1.7 Summary 
MS is the commonest cause of neurological disability in the young adults. The concept of 
MS being only an inflammatory demyelinating disease of the WM is seriously being 
challenged. There is growing evidence that MS has a neurodegenerative component that 
seems to be more responsible for the disease progression and disability. From 
pathological studies there is evidence that neurodegeneration is an early event in the 
course of disease and appears not only in the WM lesions but also in the so-called 
NAWM as well as in GM. This concept has been supported by the findings from the MRI 
studies and MR spectroscopy. The questions of which come first, inflammation or 
neurodegeneration, and their relationship with each-other are still unclear. 
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Chapter II 
Magnetic Resonance Imaging 
 
2.1 MRI and physics 
 
2.1.1 Basic principles. 
 
Magnetic Resonance Imaging (MRI) is based on the principles of nuclear magnetic 
resonance (NMR). MRI was not called nuclear MRI because of the negative connotations 
associated with the word nuclear in the late 1970's. Felix Bloch (Bloch 1946), and 
Edward Purcell, both of whom were awarded the Nobel Prize in 1952, discovered the 
magnetic resonance phenomenon independently in 1946, but it took many years later 
before Lauterbur (1974) and Mansfield (1976) would independently develop the 
technique for medical imaging. The particle of interest in the work presented is the 
hydrogen nucleus 1H  predominantly in the form of water (which makes up about 75% of 
the human body) or lipids, although other nuclei with uneven number of protons and 
neutrons such as 19F, 23Na, and 31P can also be studied with MRI, although they are less 
abundant in the biological tissues. 
1H nuclei contain a single positively charged proton. The nuclei have three intrinsic 
physical properties which are mass, charge and spin. Hence the 1H nucleus is a 
continuously rotating positive charge. The combination of spin and charge produces 
magnetism (Hashemi RH & Bradley WG, 1997).  
Magnetism and spin are related by the gyromagnetic ratio   γ: 
Magnetic moment = gyromagnetic ratio x spin 
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The gyromagnetic ratio depends on the nucleus, for (1H): γ = 42.6 MHz / tesla. The 
magnetic nuclear moment can be considered as a tiny bar magnet (Figure 2.1). The sum 
of all these tiny magnet fields is called a net magnetization.  
In the absence of a magnet field the protons are aligned randomly so the net 
magnetization is zero. The NMR phenomenon occurs when these protons are under the 
influence of an external magnetic field (usually called B0) such as the one produced by 
the main coils of the scanner, which by convention is designated as the z-axis. 
 
Figure 2.1: Vector representation of a nuclear magnetic moment 
 
 
         
 
  
 
56
This NMR phenomenon can be described in two ways - classical and quantum 
mechanics. While the quantum mechanics deals with the individual protons, the classical 
theory deals with the average, net magnetization vector. Using the quantum mechanics 
description, in the presence of an external magnetic field (B0) the protons will try to align 
themselves along the external field in two ways, based on their energy: either spin-up or 
parallel (lower energy state) or spin-down or anti-parallel (higher energy state) to B0. 
Transitions from the parallel to the anti-parallel state can be induced in the sample under 
the influence of the electromagnetic radiation of energy. This phenomenon is the 
resonance feature of NMR. 
http://en.wikibooks.org/wiki/Basic_Physics_of_Nuclear_Medicine/MRI_&_Nuclear_Me
dicine).  
Within the magnetic field (B0) there are more protons aligned parallel (i.e. low energy 
state) than anti-parallel (i.e. high energy state). Changes back to the parallel state occur 
spontaneously over a time period which is characteristic of individual tissues and their 
various pathological conditions.  
In addition to the alignment, these protons will also precess (analogous to a gyroscope 
spinning around in the earths gravitational field) about B0 at an angular frequency (ω), 
which is proportional to the main magnetic field strength and the gyromagnetic ratio for 
the 1H (γ), given by the Larmor equation:  
                                                  ω0 = γB0. 
The magnetic vector can be broken down in two components: a longitudinal or z-
component (Mz) and the transverse component (Mxy). Longitudinal magnetization is due 
to a difference in the number of protons in parallel and anti-parallel states. Due to the 
  
 
57
slight excess of parallel aligned protons (low energy) the net magnetization (macroscopic 
magnetization) has a longitudinal component aligned along the z-axis; the same as B0. 
Longitudinal magnetization (Mz) is established by placing the patient in the magnet of an 
MRI scanner only. 
 
To then generate an MRI signal, a radiofrequency pulse (RF) (short electromagnetic 
signal), usually a 90º or 180º pulse - which generates the B1 magnetic field - is applied in 
transverse (x-y) plane at a frequency that matches ω (excitation phase). Only protons that 
spin with the same frequency as the electromagnetic RF pulse will respond to the RF 
pulse. During the absorption of the energy two processes occur simultaneously: a) some 
of the protons resonate and move to the anti-parallel state resulting in the reduction of the 
longitudinal magnetization (Mz) (Figure 2.2); and b) the protons line up with each-other 
in phase producing a magnetic sum vector on the XY plane called transverse 
magnetization (Mxy), a voltage which is detected by the receiver coil placed in the 
transverse plane. It is what happens between Mz and Mxy that is of importance in MRI.  
 
2.1.2 T1 and T2 relaxation times 
Switching off of the RF pulse leads to two processes. Firstly, the excited protons 
progressively return to their lower energy level, causing re-establishment of the 
longitudinal magnetization vector Mz. The recovery of longitudinal magnetization to the 
equilibrium state (by giving back the energy they obtained from the RF pulse to their 
immediate environment - the ‘lattice’) is known as the T1 (longitudinal) relaxation time 
(Figure 2.2). Secondly, the transverse magnetization rapidly decreases (relaxation phase), 
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this is known as the T2 relaxation time (Figure 2.3). The transverse relaxation time 
constant T2 characterises the decay of magnetisation in the x-y plane to equilibrium. 
 
Although in theory the decay of transverse magnetisation should be characterised by a 
constant time T2, in reality decay is faster and is characterised by a time constant known 
as T2*. This is due to the fact that in addition to the interactions with the other magnetic 
particles, protons are subject to the inhomogeneities in the external magnetic field. The 
heterogeneous fields arise due to imperfections in the magnetic susceptibility between the 
adjacent regions in the magnetic field. To ensure that the signal differences are only due 
to spin-spin interactions and not to additional differences in the external magnetic field, 
an additional 180° pulse could be applied to reverse dephasing due to field 
homogeneities. 
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Figure 2.2  T1 (longitudinal) relaxation time 
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Figure 2.3 T2 (transverse) relaxation time 
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T1 and T2 relaxation times are inherent properties of the tissue being examined which 
vary between tissues. T1 and T2 relaxation times in addition to the proton density (PD) 
which is the concentration of the protons in a given tissue, form the basis for much of the 
contrast observed in MRI sequences. Liquids have long T1 and T2 and solids have shorter 
values as shown in table 2.1.  In brain, CSF contains H2O hence it has a long T1 and T2. 
White matter (WM) is highly structured and hence has a shorter T1 and T2. Grey matter 
(GM) contains more macromolecules than CSF hence exhibits intermediate T1 and T2 
relaxation times. MS lesions may have a decrease in structure making them detectable on 
MR images. 
 
 
Table 2.1  T1 and T2 relaxation times (ms) of different tissues 
 
 
 
 
 
 
 
 
 
 
 
Tissue  T1-relaxation time T2-relaxation time  
Fluids 1500 – 2000 (long) 700 – 1200 (long) 
Water based tissues 400 – 1200 (midrange) 40 – 200 (midrange) 
Fat based tissues 100 – 150 (short) 10 – 100 (short) 
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2.1.3 Imaging sequences  
 
Spin echo (SE) sequence is routinely used in MRI. In order to obtain a SE sequence an 
initial excitatory 90° RF pulse is given, followed by a second 180° refocusing pulse.  
 
Figure 2.4: Spin Echo sequence 
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The 90° pulse applied along the x-axis produces transverse magnetisation along the y- 
axis (T2 relaxation time). The transverse magnetisation dephases (T2 decay) due to time-
invariant local inhomogeneities. A 180° pulse given at a time τ from the 90° pulse along 
the x-axis flips the spins from close to the y-axis to –y axis. The spins continue to precess 
in the same direction and at the same speed as before the 180° was applied, leading to the 
rephasing of the transverse magnetisation. The spins totally rephase along the –y-axis, to 
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give a spin echo signal which can be acquired (echo time TE). The time between two 
excitation 90° pulses represents the repetition time (TR).  
 
TE and TR are important scan acquisition parameters. By varying these values we are 
able to weight images based on the T1 and T2 characteristics of the material imaged. 
These two parameters (TE and TR) determine the appearance of a spin echo image; 
different combinations of TE and TR will produce different degrees of contrast (intensity 
difference) between tissues.  Changing TR will change the contrast between tissues with 
different T1 relaxation times, changing TE will change the contrast between tissues with 
different T2s. TR is almost always longer than TE.  
The signal is always proportional to PD. To produce a PD-weighted image, a short TE 
(avoids T2-weighting) and a long TR (avoids T1-weighting) are acquired. To produce a 
T1-weighted image in which the intensity contrast is due mainly to the T1 relaxation 
properties of the tissue a short TE and TR are acquired. A long TE and TR will produce a 
T2-weighted image in which the intensity contrast is due mainly to the T2 properties of the 
tissue.  
 
2.1.4 Gradient and image formation 
The gradients are magnetic fields that change from point to point, usually in a linear 
manner. During the acquisition, while the magnetic field B0 is constantly present, the 
gradient pulses are applied in a controlled fashion to form an MR pulse sequence (MRI 
from picture to proton). The gradients used in MRI allow for an image to be constructed. 
Three orthogonal gradient coils (slice-select, phase encoding and frequency [read or 
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readout] encoding gradient) are used to allow three-dimensional spatial encoding in the x, 
y and z directions.  
The slice-selective gradient, turned on during the RF pulse, allows excitation of a slice of 
tissue corresponding to the bandwidth of the slice-selective RF pulse, exciting those 
protons at the Larmor frequency of the RF pulse. Doing this sequentially with successive 
excitations selects slices in a predetermined manner to cover the tissue under 
examination. Slice thickness is dependent on the RF pulse bandwidth and the amplitude 
of the slice-select gradient. 
 
The frequency-encoding gradient is applied after the slice-select gradient when the echo 
is being received. This causes differing precession frequencies along the axis such that 
each part of the sample has a different frequency. It is only applied when the signal is 
measured, and hence the signal strength at each frequency can be measured. 
 
The phase encoding gradient is applied after the RF pulse excitation and before the 
frequency-encoding gradient and provides spatial information about the orthogonal 
direction  by causing a phase shift of the protons, with protons at different positions in the 
gradient precessing at different frequencies. The process is repeated with phase-encoding 
gradients of increasing amplitude, with a separate TR necessary for each encoding step, 
except for single shot techniques. The matrix of an image describes the number of 
frequency encodes x the number of phase encodes (most commonly 256 x 256). 
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The vector of application of the three gradients dictates the plane of imaging undertaken 
(axial, sagittal, coronal or oblique). For two-dimensional (2D) imaging the slice-select 
gradient only determines the plane whilst the other gradients determine the in-plane 
orientation. For 2D imaging we usually use frequency-encoding for one direction and 
phase-encoding in the other whilst for three-dimensional (3D) images we use frequency-
encoding in one direction and phase-encoding in the remaining two. 
 
For each TR, a line of data is stored in a computer as a series of numbers. This is repeated 
till all the data set is built up. This data does not correspond to the image and in order for 
this data to be transformed into an image it must be converted from time-domain to the 
frequency-domain using a mathematical process known as Fast Fourier Transform (FFT). 
The image consists of a matrix (number of pixels) with a field of view (FOV) that defines 
the dimensions of the area studied. FOV = number of pixels * voxel size.  
 
2.1.5 Signal to noise ratio 
Signal to noise ratio (SNR) is a measure of signal strength relative to background noise. 
SNR can be measured from the ratio of the mean voxel signal (from a homogeneous 
region with high signal intensity within the object of interest) divided by the SD of the 
background signal (measured from several regions outside the object). Noise is the 
undesired signal resulting from the MR system, the environment and the patient. It occurs 
at all frequencies and randomly in time. To increase the SNR usually requires increasing 
the signal relative to the noise. Parameters that affect the SNR are: the field strength, 
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proton density, coil type and position, TR, TE, flip angle, number of signal averages and 
receive bandwidth. 
 
2.1.6 Contrast to noise ratio 
Contrast-to-noise-ratio (CNR) is the ratio of the difference in signal intensity between 
regions with different tissues, and the background noise. CNR is the most important 
aspect of image quality.  
It is controlled by the same factors that affect SNR. CNR is probably the most important 
image quality factor as the objective of any examination is to produce an image where 
pathology is clearly seen relative to normal anatomy. Visualization of a lesion increases if 
the CNR between it and surrounding normal tissue is high.  CNR can be increased by the 
T1 or T2-weighting, administration of a contrast agent, magnetization transfer contrast 
and chemical suppression techniques. 
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2.2 Conventional MRI techniques in MS 
2.2.1  T2-weighted images 
Whilst T1-weighted images (see 2.2.2) were the first application of the MRI in MS, 
(followed by T2 and PD-weighted SE images), T2-weighted images are now the gold 
standard sequences for depicting the WM lesions. The images with very little T1 or T2-
weighting are often called PD-weighted images although all the images have intrinsic 
PD-weighting properties (Tofts P, 2003). On the T2 and PD-weighted images, MS lesions 
appeared as hyperintense areas called T2 lesions (Figure 2.5) (Bailes et al., 1982).  
 
The T2 contrast can be achieved using SE, fast spin-echo (FSE) or fast fluid attenuated 
inversion recovery (FLAIR). Acquisition of a FSE requires the utilization of multiple 
180° refocusing pulses, which allows filling of multiple lines of data in one shot; 
typically between 2-16 lines of data can be filled per TR.  The scanning time is a function 
of TR, number of excitation and phase encodings. By performing the same number of 
phase encodings but with more than one phase encoding per TR, the acquisition time in 
FSE is reduced with no reduction in SNR compared to the conventional SE. The 
increased speed also allows high resolution imaging not achievable with conventional SE. 
 
Clinically silent T2 WM hyperintense lesions are present in 50-70 % of people who 
present with a clinically isolated syndrome (CIS) typical of MS such as optic neuritis 
(ON), brainstem syndrome (BS) and spinal cord syndrome (SC) (Jacobs et al., 1986; 
Miller et al., 1987; O'Riordan et al., 1998b; Ormerod et al., 1986a) and their presence 
indicates a higher likelihood of developing clinically definite MS (Brex et al., 2002; 
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Jacobs et al., 1997; Minneboo et al., 2004; Morrissey et al., 1993; O'Riordan et al., 
1998b; Soderstrom et al., 1994; Swanton et al., 2007). 
 
MRI remains the most important paraclinical tool in diagnosing MS. Different MRI 
criteria have been designed to assess the likelihood of the visible MRI lesions being as a 
result of MS (Barkhof et al., 1997; Fazekas et al., 1988; Paty et al., 1988). More recently 
the McDonald Criteria (McDonald et al., 2001) (which were later on revised (Polman et 
al., 2005; Polman et al., 2011)) have been developed presenting a scheme to better and 
more reliably diagnose MS. These criteria formally incorporated the MRI features in the 
established diagnostic workup which includes the neurological history and examination 
and the use of paraclinical laboratory examination in order to establish the dissemination 
in time and space which are crucial for the diagnosis of MS. 
But, while these T2 lesions predict conversion to clinically definite MS (Swanton et al., 
2007), they only predict subsequent disability to a limited degree (Brex et al., 2002; 
O'Riordan et al., 1998c). Whilst pathological studies have confirmed that these T2 lesions 
correspond with the MS plaques,  (Ormerod et al., 1987), these lesions lack pathological 
specificity being driven by inflammation, demyelination, oedema as well as axonal loss 
and remyelination (Barkhof et al., 2003). These could explain at least partially the modest 
correlation of these lesions with disability. Also, most of the studies have been short to 
medium term and as disability in MS accrues slowly, longitudinal studies are needed to 
fully assess the potential of MRI in predicting disability. 
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WM T2 lesion load has frequently been included in treatment trials to assess the response 
to the disease modifying treatment and assess disease progression (Comi et al., 2001; 
Jacobs et al., 2000a; Kappos et al., 2006b). 
 
Whilst the presence of demyelinating lesions in the cortex has been known for a long 
time (Brownell & Hughes, 1962), their significance has been largely ignored. This is due, 
at least partially, to the fact that on the conventional MRI most of lesions in the GM are 
not visible (Geurts et al., 2005) and despite improved sequences they remain largely 
undetected (Geurts et al., 2005; Geurts et al., 2008). Certainly, other factors such as poor 
visualization of these lesions with the conventional histological staining methods has 
played a role on disregarding these lesions for a long time (Geurts & Barkhof, 2008). 
 
2.2.2  Spin-Echo (SE) and T1-weighted images 
T1-weighted inversion recovery images, which identify the MS lesions as areas of 
hypointensity compared to the normal white matter, were the first application of MRI in 
MS patients (Young et al., 1981). 
The persistent hypointense lesions seen on the now widely used T1-weighted SE 
sequence seem to represent areas of greater tissue matrix damage including axonal loss 
(Bruck et al., 1997) (van Waesberghe et al., 1999) and in some studies (but not in all of 
them (O'Riordan et al., 1998a)) have shown better correlation with disability than T2 
lesions (Truyen et al., 1996). 
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2.2.3  Enhanced images 
Gadolinium (Gd) a paramagnetic element, (which has seven unpaired electrons in its 
electronic structure) that when chelated to, for example, diethylene-triamine-pentacetic-
acid (DTPA; one of a number of chelates currently used) to eliminate the toxic effects of 
free Gd, is used as contrast agent in MRI. Chelated Gd is given intravenously; despite 
being too large a molecule to cross the blood-brain barrier quickly, it can slowly leak out 
into brain tissues but rapidly accumulates in lesions where the blood-brain barrier is 
disrupted resulting in “enhancement” of the active MS lesions (Fig 2.5) (Bruck et al., 
1997). The effects of the paramagnetic Gd, is to decrease the T2 and T1 relaxation times 
of the protons in the immediate vicinity of the molecule. Due to the protons exchange 
with other protons there is an overall reduction of T1 and T2. At usual doses 
(0.1mmolGd/kg) the major effect of the Gd is the reduction of T1 in tissues where it 
accumulates, so on post-contrast T1-weighted images the lesions will have enhanced 
signals, (i.e. appear hyperintense).  
Gd enhanced lesions are used in MS treatment trials to monitor the disease activity. Gd-
enhancement has been associated with histopathological evidence of active inflammation 
and demyelination (Bruck et al., 1997; Katz et al., 1993) and is a consistent feature of 
new lesions (lasting typically for several weeks) in relapsing forms of MS (Kermode et 
al., 1990; Miller et al., 1988b; Thorpe et al., 1996). 
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Figure 2.5  PD-weighted image (left) and SE T1-weghted images pre (central image) and 
20 minutes post intravenous contrast (right) showing two Gd-enhancing lesion (left 
image).  
 
NB: The same lesions are marked with an arrow on the corresponding PD-weighted 
image where they appear as hyperintense. Note that no hypointense lesions are seen in 
the non-contrast SE image. 
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2.3 Quantitative Imaging Techniques  
2.3.1 Atrophy  
Brain atrophy is well recognized not only in established MS but also in CIS patients who 
convert to MS (Dalton et al., 2004). Although atrophy is apparent at earlier stages of 
relapse-onset MS, is maybe more evident at later stages (Dalton et al., 2006). Whole 
brain atrophy, as well as tissue specific (i.e. grey matter (GM) and white matter (WM)) 
and regional atrophy has been observed at different stages of MS (Bakshi et al., 2001; 
Carone et al., 2006; Chard et al., 2004; Dalton et al., 2004; Fisher et al., 2008; Sastre-
Garriga et al., 2005; Zivadinov et al., 2004). Some studies have shown the rate of atrophy 
been the same across the different subtypes of MS (Kalkers et al., 2002) although other 
studies have shown more atrophy in the progressive forms (Dalton et al., 2006; Fisher et 
al., 2008). 
 
Although MS has classically been seen as a WM disease, there is growing evidence that 
there is an extensive involvement of the GM in MS, (as well as normal appearing WM 
(NAWM)), and also that the GM pathology is more clinically relevant. GM atrophy in 
particular seems to be a better predictor of disability than WM atrophy and T2 lesions 
(Pirko et al., 2007; Sanfilipo et al., 2005). While brain atrophy may be mainly driven by 
neurodegeneration, brain volume is also affected by other factors such as oedema, 
inflammation and demyelination, although to a lesser degree. Brain atrophy has been 
suggested as a potential surrogate marker of disability progression in MS and 
increasingly has been included in treatment trials in MS especially of the progressive 
forms (Altmann et al., 2009; Furby et al., 2008; Kapoor et al., 2010).  
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The spinal cord is frequently involved in MS patients and is an important element of the 
acquired disability. Cervical cord atrophy is observed in MS. Sequences such as fast-
spoiled gradient echo images have been used to assess the size of the cord and 
reproducible techniques such as Losseff technique (Losseff et al., 1996) have shown that 
the cervical cord atrophy was strongly correlated with disability. 
 
2.3.2  Magnetization transfer imaging 
Traditionally MRI uses the T1 and T2 relaxation times and proton density (PD) of tissue 
water (hydrogen protons) to generate contrast. Magnetization transfer (MT) imaging is an 
additional way of obtaining tissue contrast based on the fact that tissues contain two or 
more separate populations of hydrogen protons: the free highly mobile (water) hydrogen 
pool, and the immobile restricted hydrogen pool, such as  those protons bound to large 
macromolecular proteins and lipids (such as myelin), found in cellular membranes. The 
macromolecular pool has very short relaxation times (a very short T2) and is therefore 
invisible to conventional imaging. It can be measured indirectly by the use of an off-
resonance radiofrequency pulse capable of selectively saturating the macromolecular 
proton pool. Magnetization transfer (MT) contrast uses additional RF pulses (these pulses 
are either applied at a frequency away from the Larmor frequency where they are known 
as off-resonant, or nearer to the centre frequency where they are known as on-resonant) 
to suppress hydrogen protons that are not free but bound to macromolecules and cell 
membranes. As a result of the application of these pulses, reduced magnetization is 
transferred to the MR visible free protons (via exchange with the macromolecular pool) 
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suppressing the signal in certain types of tissues. The difference (percentage reduction) in 
the observed signal intensity (of an identical image) before and after the saturation pulse 
(with and without the saturation) is the magnetization transfer ratio (MTR), which 
reflects, at least partially, the density of the macromolecular protons in a given tissue.  
 
Although MTR is the result of the combination of several physical quantities and it is 
highly dependent on the acquisition sequence parameters, it has nevertheless proved to be 
a sensitive marker of pathological change in the sense that it decreases with increasing 
histopathological changes (Schmierer et al., 2004; van Waesberghe et al., 1999). A 
reduction in a tissue’s macromolecular content will result in a lower MTR and, consistent 
with this, a low MTR is associated with demyelination and a reduction in axonal density 
(Mottershead et al., 2003; van Waesberghe et al., 1999) and to a lesser extent 
inflammation (Schmierer et al., 2007). 
 
The normalized histogram - a frequency distribution showing the number of voxels with 
a particular range of MTR parameters values - is a widely used technique to depict brain 
MTR. Whole brain histogram analysis (any information on the location of abnormalities 
is lost in this case) and GM, WM and lesion histograms can be acquired. MTR changes 
are observed at all stages of MS: CIS patients at high risk of converting to MS (Fernando 
et al., 2005), early relapsing-remitting MS (Davies et al., 2004)  and progressive stages. 
GM (as well as in deep GM (Audoin et al., 2007)) and NAWM reduction in MTR are 
observed at all stages of MS and seem to reflect the disease phenotype: the histogram 
metrics are more severely affected the more patient is disabled i.e. abnormalities in 
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SPMS>RRMS>CIS (Cercignani et al., 2001; Ge et al., 2002; Traboulsee et al., 2002). 
MTR changes especially of the GM seem to correlate better with disability  (Ge et al., 
2001a; Khaleeli et al., 2007b).  
 
MTR changes are also observed in MS lesions and these seem to correlate to some extent 
with disability (Gass et al., 1994). 
 
Other techniques apart from histograms, such as the use of principal component analysis 
– which maximizes the variability between histograms – have been reported to improve 
the correlation between whole brain MTR and disability measures (Dehmeshki et al., 
2001). 
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PART II 
 
RELATIONSHIP BETWEEN LONGITUDINALCHANGES IN WHITE MATTER 
LESION LOAD AND DISABILITY AT 20 YEARS 
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Chapter III 
Disability and T2 MRI lesions: a 20 year follow up of patients with relapse-onset of 
MS. 
Introduction 
As discussed in the previous chapter (Chapter 1) clinically isolated syndromes (CIS), 
such as optic neuritis, brainstem or spinal cord syndromes are frequently the first clinical 
presentation of MS. However,  not all CIS patients convert to MS and in those who do, 
disability is highly variable (Boiko et al., 2002; Confavreux & Vukusic, 2006; 
Kremenchutzky et al., 2006; Nilsson et al., 2005; Runmarker & Andersen, 1993; 
Weinshenker et al., 1989) and limited prognostic information is provided by early clinical 
features such as the type of CIS, frequency of early relapses and disability status 5 years 
after onset.  
 
Numerous studies have investigated the prognostic role of MRI in CIS patients, most 
with follow up of a few years only. Clinically silent T2-weighted brain white matter 
lesions are present in 50-70% of CIS patients (Jacobs et al., 1986; Miller et al., 1987; 
Ormerod et al., 1986a) and their presence indicates a higher likelihood of developing 
clinically definite MS (Beck et al., 2003; Brex et al., 2002; Jacobs et al., 1997; Minneboo 
et al., 2004; Morrissey et al., 1993; Soderstrom et al., 1994).  
 
To assess the potential of MRI to predict disability due to MS requires prolonged follow 
up, since on average disability accrues only slowly in MS. Tintore et al (2006) followed 
up 156 patients with CIS after a mean of 7 years and they found that baseline brain MRI 
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findings helped to differentiate patients with low, medium and high risk for conversion to 
MS. The number of brain lesions best predicted 5 year disability  (Tintore et al., 2006).  
Minneboo et al reported on 42 CIS patients followed up 8.7 years  later and showed that 
two or more infra-tentorial lesions best predicted long-term disability (Minneboo et al., 
2004). Another long term follow up study of 30 patients with relapsing remitting MS 
reported that T2 lesion volume correlated strongly with brain tissue loss and clinical 
disease severity 13 years later (Rudick et al., 2006a)  
 
 In a previous report based on data from 14 year follow up of a prospectively recruited 
CIS cohort, EDSS score at 14 years correlated moderately with lesion volume in MRI at 
5 years (rs = 0.60) and with increase of lesion volume over the first 5 years (rs = 0.61) 
(Brex et al., 2002). I followed up this same CIS cohort and I report here the findings after 
20 years. The overall aim was to investigate whether the longitudinal relationships 
between the MRI and clinical course were maintained over a uniquely long period of 20 
years and to assess how lesions evolve in relation to natural history. This investigation 
includes a comparison of the rate of lesion volume change over time in three distinct 
subgroups classified according to their clinical status at last follow up: CIS, RRMS or 
SPMS. 
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Methods 
Subjects 
One hundred and forty CIS patients were recruited between May 1984 and July 1987 and 
had a clinical assessment and brain MRI performed (Miller et al., 1987; Ormerod et al., 
1986b; Ormerod et al., 1986a; Ormerod et al., 1987). A follow up was performed 
approximately one year later in 109 patients (53 optic neuritis; 23 brainstem syndrome 
and 33 spinal cord syndrome), who had a clinical examination and brain MRI scan 
repeated at this time (Miller et al., 1988a; Miller et al., 1989). Subsequent follow ups 
were performed after 5 (89 patients) (Morrissey et al., 1993), 10 (81 patients) (O'Riordan 
et al., 1998c) and 14 years (71 patients) (Brex et al., 2002). 
 
I wanted to follow up - after 20 years - those patients in whom the baseline scans and 
adequate clinical information of the first clinical episode were still available. The study 
was approved by the National Hospital for Neurology and Neurosurgery and Institute of 
Neurology Joint Research Ethics Committee. The NHS Strategic Tracing System, which 
is a database of people, places and organizations in England and Wales, was used in those 
cases where the contact details were missing or found to be incorrect. Approval for 
access to this database for research purposes was obtained from the Security 
Confidentiality Advisory Group of the NHS Information Authority (the Research Ethics 
Committee also approved the use of the NHS Strategic Tracing System for research 
purposes). 
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Special precaution was needed when approaching those who had been seen at baseline 
and year 1 and 5 but not at years 10 or 14. During the period covering the earliest time-
points of this follow up (i.e., the baseline, year 1 and year 5 assessments that were 
performed from the mid 1980s to the early 1990s), it was not routine practice to provide 
patients with information about the link between CIS and MS, nor was there a standard 
patient information sheet for recruitment which contained this information. Some 
participants in the study might therefore still have been unaware of the association of 
their symptoms with MS. It was also uncertain whether subjects would expect, or be 
sympathetic to, contact from us some 15 or more years after the last time they had been 
seen. Thus with the Research Ethics Committee approval, the initial contact with such 
individuals was by a letter which did not provide full details of the project, or mention 
MS, but simply asked them to get in touch if they were interested in being followed up. 
Those people who replied positively to this initial approach were invited for clinical 
examination and brain MRI at which point further information was provided, including 
the relevance of the study to MS. With those patients who did not reply either positively 
or negatively to two letters of invitation, I made an attempt to contact them either by 
phone or through their general practitioner. 
 
Of the 140 subjects who were identified and had been initially recruited with a CIS for a 
baseline MRI study, 8 were excluded because they had either at baseline or developed 
subsequently another non-MS diagnosis: 3 at baseline - pontine arteriovenous 
malformation, pontine haematoma and Leigh’s disease; 3 at 5 years - myasthenia gravis, 
cerebrovascular disease and HIV related complications; one at 10 years - systemic lupus 
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erythematosus and one at 14 years - cerebrovascular disease. Six other patients had died 
from non-MS related disease (3 between years 1 and 5 and 3 between years 14 and 20) 
and there was insufficient information to determine their prior neurological status. Of the 
remaining 126 subjects, 3 were abroad and could not be traced; 2 did not reply to a 
second letter of invitation and no contact number was available; one was contacted but 
did not wish to be followed up; the contact details were unobtainable in 9; and either the 
baseline scan could not be located or adequate clinical information on the first 
presentation was not available in 4 subjects.  
 
The remaining 107 patients were included in the study: 104 who were living at the time 
of the 20 year assessment, and 3 who were known to have died from the complications of 
severe MS at an earlier timepoint. Of these 107 subjects, the first follow up was after 1 
year for 92, 5 years for 7, 10 years for 3 and 20 years for 5 subjects. The disease duration 
(from CIS onset) at the 20 year follow up was a mean of 20.2 years (range 18 to 27.7 
years). 
 
Clinically definite MS was diagnosed by using Poser criteria and was based solely on 
clinical evidence (Poser et al., 1983). This required a second clinical episode with 
objective new neurological signs i.e. clear evidence for dissemination in time and space. 
Patients who did not develop clinically definite MS were classified as remaining CIS at 
the 20 year follow up. Because the primary focus was to explore the relationship of MRI 
findings with the clinical course and natural history, MRI evidence only for 
dissemination in space and time (Polman et al., 2005) was not used to diagnose MS. In 
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those who developed MS, the clinical course, either relapsing remitting or secondary 
progressive, was determined by Lublin and Reingold criteria (Lublin & Reingold, 1996). 
Disability status was determined for all subjects by using EDSS (Kurtzke, 1983) and 
MSFC (Fischer et al., 1999). RRMS with an EDSS ≤ 3 was defined as benign MS.  
 
MRI Protocol 
Baseline and 5 year MRI scans were obtained on a 0.5 Tesla (T) scanner (Picker, 
Cleveland) and on a 1.5 T GE Signa Echospeed scanner (General Electric Signa, 
Milwaukee) at 10, 14 and 20 years (Table 3.1). Contiguous, axial slices covering the 
whole brain were obtained at all visits. In a minority of early baseline scans (1984/1985) 
slice thickness was 10 mm; it was 5 mm for all subsequent scans. At 20 years T2-
weighted, dual-echo fast spin-echo sequences (FSE) of the brain were obtained on 75 
patients (TR 2000ms; TE 17/102ms; 28 x 5 mm [matrix 256 x 256, FOV 24 x 18 cm, 1 
NEX]). Of the remaining 32 subjects included in the 20 year clinical follow up, 3 had 
died of severe MS; one had become claustrophobic  and the remainder could not be 
scanned either because of severe disability (8 subjects) or because lived too far away (20 
subjects). In these patients phone EDSS was obtained. Identification of the lesions on the 
hard copies was performed by me and it was checked for consistency by an experienced 
neuroradiologist who was blinded to the clinical details. Marking of the lesions was done 
on the short echo image with the long echo image used as a reference, by myself. 
Baseline MRI was classified as abnormal if it displayed one or more clinically silent 
lesions compatible with demyelination. A normal scan might include the CIS 
symptomatic lesion only. T2 lesion volume was measured from electronic images using a 
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semi-automated contouring technique to outline lesions, previously described (O'Riordan 
et al., 1998a; Sailer et al., 1999). The 20 year T2 lesion volume was not measured in one 
patient in whom cerebrovascular disease developed as a second pathology. 
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Table 3.1 T2-weighted images and their parameters at all follow up time-points 
 
Time-point Scanner strength 
(Tesla) 
Sequence TR 
(ms) 
TE 
(ms) 
Slice thickness 
(mm) 
Baseline 
May 1984 - Aug 1987  
0.5T (Picker Cleveland) SE 2000 60 5 or 10 
1 year follow-up 
Nov 1984 - Dec 1987 
0.5T (Picker Cleveland) SE 2000 60 5 
5 year follow-up 
Jan 1990 - Jul 1991 
0.5T (Picker Cleveland) SE 2000 60 5 
10 year follow-up 
Jun 1995 - Nov 1996 
1.5T (General Electrical 
Signa, Milwaukee) 
FSE 2000 30/90 5 
14 year follow-up 
Jan 1999 - Jul 2000 
1.5T (General Electrical 
Signa, Milwaukee) 
FSE 2000 19/95 5 
20 year follow-up 
Nov 2004 - Apr 2007  
1.5T (General Electrical 
Signa, Milwaukee) 
FSE 2000 17/102 5 
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Statistical Analysis 
The data was analyzed using the standard statistical software package (SPSS 12, Chicago, 
IL) and Stata 9.2 (Stata Corporation, College Station, Texas, USA). Spearman rank-
correlation was used to evaluate the correlation of the lesion volume or change of lesion 
volume, on brain MRI, with the EDSS and MSFC score. Because of the skewed (non-
normal) nature of T2 lesion volume data, a non parametric test, Cuzick’s test, was used to 
look for a linear trend across the 3 groups of patients (defined as CIS, RRMS or SPMS at 
20 years), to assess whether the lesion variable is associated with these different clinical 
courses; and the Wilcoxon rank-sum test was used to compare the rate of lesion volume 
increase between these groups. Longitudinal linear mixed models were used to compare 
rates of change in lesion volume, with T2 lesion volume as response variable and time 
and patient group terms as covariate, using all available data-points for the T2 lesion 
volume. A quadratic term was fitted in addition to the linear term in the model for the T2 
lesion volume over time to assess if there was non-linearity in lesion growth. Bootstrap 
confidence intervals were obtained where residuals showed signs of non-normality. 
Bootstrap derived p-values are given as ranges, or to fewer decimal places, due to the 
computer-intensive nature of the method. 
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Results 
The cohort followed up at 20 years was similar to that seen at baseline in terms of mean 
age of disease onset, gender, type of syndrome and frequency of abnormalities on MRI at 
presentation (Table 3.2). Disability was assessed by examination on 77 patients. EDSS 
only was assessed by telephone on 27 patients who were unable to attend the hospital for 
a clinical examination (Lechner-Scott et al., 2003). Three who had already died from 
severe complications of MS (Brex et al., 2002) were assigned an EDSS of 10. Three 
patients were on disease modifying treatment (2 had RRMS and one had SPMS). Another 
patient had stopped medication three years before the time of examination, after entering 
secondary progressive stage. The 75 patients who had MRI at 20 years were compared 
with the 29 who were not scanned at 20 years in terms of the baseline demographic 
features: the groups were similar with regard to age, gender and frequency of baseline 
MRI abnormalities, while the scanned group had a high percentage with optic neuritis 
(55% vs. 41%) and a lower percentage with brainstem presentations (19% vs. 31%). The 
median EDSS at year 20 was 2.5 in the scanned group and 5.5 in the non-scanned group, 
higher disability in the latter group reflecting the fact that disability precluded scanning a 
number of patients. 
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Table 3.2  Characteristics of the cohort at each follow up time-point 
 
Characteristic Baseline 1  
Year 
5.3  
Year 
9.7  
Year 
14.1  
Year 
20.2  
Year 
Patients who underwent clinical 
assessment - no. 
140 109 89 81 
 
71 
 
107 
Exclusion due to alternative 
diagnosis - no 
3 0 3 1 1 0 
Deaths not related to MS - no 0 0 3 0 0 3 
Female sex - no. (%) 80 (60) + 68 (62) 53 (60) 53 (65) 49 (69) 71 (66) 
Mean age at presentation. 
   Range 
32+ 
13-49 
32 
13 - 49 
31 
13 - 49 
32 
17 - 49 
32 
19 - 49 
32 
13-49 
Optic neuritis - no. (%) 
Brain stem syndrome - no. (%) 
Spinal cord syndrome - no. (%) 
69 (50) 
33 (24)§  
38 (28) 
53 (49) 
23 (21) 
33 (30) 
44 (49) 
17 (19) 
28 (31) 
42 (52) 
16 (20) 
23 (28) 
36 (51) 
14 (20) 
21 (30) 
54 (51) 
25 (23) 
28 (26) 
MRI examinations - no. 140 109 89 64 55 75 
Electronic data for lesion 
volume quantification - no 
 
74 
 
---* 
 
69 
 
63 
 
55 
 
75 
Abnormal results-baseline MRI-
no. (%) 
 Optic neuritis - no. (%) 
 Brain stem syndrome - no. (%) 
 Spinal cord syndrome - no. (%) 
85 (64) + 
 
42 (64)   
23 (77)   
20 (54)   
69 (63) 57 (64) 54 (67) 50 (70) 73 (68) 
 
36 (67) 
20 (80) 
17 (61) 
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Conversion to clinically definite 
MS - all patients - no. (%) 
   Abnormal scan at baseline 
   Normal scan at baseline 
 
--  
-- 
-- 
 
21 (19) 
21 (30) 
0 
 
38 (43) 
37 (65) 
1 (3) 
 
48 (59) 
45 (83) 
3 (11) 
 
48 (68) 
44 (88) 
4 (19) 
 
67 (63) 
60 (82) 
7 (21) 
Lesion volume on MRI - cm3 
   Median 
   Range 
 
0.43 
0-55 
 
---- 
 
1.9 
0-114.3 
 
4.3 
0-88.6 
 
6.01 
0-70.2 
 
7.2 
0-60.8 
Median EDSS score 
   All patients 
   Clinically definite MS 
 
0# 
- 
 
- 
- 
 
1.5 
2.5 
 
2 
3.25 
 
2 
3.25 
 
3 
4.0 
 
* Lesion volume measures not available at year 1 
+ Based on 133 patients (Apart from CIS type, demographic data was no longer available 
in 5 patients who were excluded at an earlier time point due to an alternative non-MS 
diagnosis and 2 who died of non-MS cause before 5 years follow-up) 
§ Includes 3 patients excluded after baseline MRI revealed a non-MS diagnosis 
# As EDSS was not measured during the CIS presentation, 0 represents the presumed 
EDSS immediately prior to CIS. This value was used to evaluate change of EDSS from 
baseline to year 5 
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Conversion to CDMS and disability status 
After 20 years, clinically definite MS developed in 67/107 patients (63%). The remaining 
40 patients were classified as still CIS – this included 5 with “clinically probable” MS by 
the Poser criteria that had experienced new neurological symptoms but with no new signs 
or disability. Clinically definite MS developed in 35/54 (65%) who initially presented 
with optic neuritis, 15/25 (60%) with a brainstem syndrome and 17/28 (61%) with a 
spinal cord syndrome. The median EDSS score of the MS group was 4.0 (range 0-10): 39 
(58%) had RRMS and 28 (42%) had SPMS. Twenty six/67 (39%) of patients with 
clinically definite MS had an EDSS score of 6 or more and 26/67 (39%) had an EDSS 
score of 3 or less. The median EDSS score of the SPMS group was 6.5 (this includes 
three patients who died of severe complications of disease in whom an EDSS of 10 was 
assigned). The median EDSS of the optic neuritis onset MS group was 4.0 and in the 
non–optic neuritis MS group was 5.0 (p = 0.28, Wilcoxon rank-sum test). 
 
Normal Brain MRI scans at baseline 
Clinically definite MS developed in 7/34 (21%) patients with normal brain MRI scan at 
baseline, (4 presented with optic neuritis and 3 with spinal cord syndrome). The median 
EDSS of this MS group was 3.5 (range 1.5 to 7.5) and the median time to converting to 
MS was 6.0 years (range 1 to 11).  
 
 
 
 
  
 
90
Abnormal Brain MRI scans at baseline 
Clinically definite MS developed in 60/73 (82%) patients with an abnormal brain MRI 
scan. Their median EDSS was 4.25 (range 0 to 10) and median time to converting to MS 
was 2 years (range 0.5 to 14 years). 
 
Baseline MRI lesion number and clinical outcome 
Table 3.3 shows the relationship between baseline lesion number (grouped as 0, 1-3, 4-9 
and ≥10) and clinical outcome at 20 years (CIS or clinically definite MS; those with 
EDSS > 3 or ≥6).  
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Table 3.3  Baseline MRI lesion number and clinical status at 20 years 
 
No. of Brain T2 lesions at baseline  
0 
N=34 
1-3 
N=22 
4-9 
N=20 
10+ 
N=31 
No. CIS at 20 years 27 
(79%) 
4 
(18%) 
3 
(15%) 
6 
(19%) 
No. clinically definite 
MS at 20 years 
7 
(21%) 
18 
(82%) 
17 
(85%) 
25 
(81%) 
No. with EDSS >3 at 20 
years 
9 
(26%) 
8 
36%) 
10 
(50%) 
20 
(65%) 
No. with EDSS ≥ 6 at 
20years 
2 
(6%) 
4 
(18%) 
7 
(35%) 
14 
(45%) 
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Longitudinal changes 
Patients who developed SPMS tended to have larger baseline T2 lesion volumes and a 
greater increase of lesion volume especially over the first 5 years - this was even more 
evident for those patients who died of complications of MS (Table 3.4 & Figure 3.1). 
Observing the pattern of  median T2 lesion volume change over 20 years showed that 
although at baseline there was some overlap, from 5 years onwards the groups of patients 
(CIS, RRMS, SPMS) were well distinguished. The SPMS group showed a steeper rate of 
lesion volume increase than RRMS. The increase in SPMS was higher than in RRMS 
over the first 5 years of the disease (p = 0.008, Wilcoxon rank-sum test).  
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Table 3.4  MRI lesion volumes at each study time-point displayed according to clinical 
subgroup classification at 20 year follow up 
 
Clinical outcome Baseline 5 years 10 years 14 years 20 years 
CIS - No. 
Median volume (cm3) 
Range (cm3) 
27 
0 
0-2.2 
21 
0 
0-10.8 
18 
0.07 
0-16.3 
15 
0.18 
0-15.1 
30 
0.5 
0-13.8 
26 
0.7 
0-13.7 
26 
2.06 
0.1-36.5 
28 
5.1 
0.55-40.6 
25 
6.09 
0.97-37.8 
33 
12.7 
0.2-60.8 
18 
0.7 
0-13.7 
18 
1.8 
0.5-36.5 
20 
4.5 
0.5-40.6 
17 
5.8 
0.9-37.8 
22 
8.7 
0.2-60.8 
RRMS (All) - No. 
Median volume (cm3) 
Range (cm3) 
RRMS (EDSS≤3) - No. 
Median volume (cm3) 
Range (cm3) 
RRMS (EDSS>3) - No. 
Median volume (cm3) 
Range (cm3) 
8 
0.5 
0-4.07 
8 
2.7 
0.1-12.4 
8 
6.2 
0.5-19.9 
8 
9.7 
1.5-23.1 
11 
17.5 
4.7-47.6 
SPMS - No. 
Median volume (cm3) 
Range (cm3) 
     20* 
2.5 
0-55 
      17* 
17 
0-114 
      14§ 
18.9 
0.4-88.6 
       13 
27.7 
0.5-70.2 
      11 
34.4 
0.5-56.4 
 
* Includes three patients who died of MS  
§ Included one patient who died of MS  
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Figure 3.1  Median T2 lesion volume (T2LV) (cm3) over time for patients groups 
 
 
NB: Bars show Inter-quartile range; Numbers of patients shown 
 
 
 
 
 
 
 
 
 
  
 
95
Cuzick’s test was used to look for a linear trend across the three MS subgroups - benign 
and non-benign RRMS and SPMS - for those patients in whom the baseline and 20 years 
T2 lesion volume was available. It showed an increase in lesion growth from the benign 
group, through the non-benign RRMS group (EDSS > 3), to the SPMS group (p = 0.08). 
Lesion growth over 20 years showed a trend to be higher in SP than RRMS (for the latter, 
benign and non-benign subgroups were combined; p = 0.07, Wilcoxon rank-sum test) and 
in benign versus non-benign RRMS (p = 0.08).  
 
A longitudinal analysis of the gradients, using all available data points, estimated the rate 
of growth in the RRMS group as 0.80cm³ per year [bootstrap 95% CI: 0.63, 0.99; 
P<0.001] while in the SPMS group it was estimated as 2.89 cm³ per year [bootstrap 95% 
CI: 1.78, 4.01; P<0.001]. This is a difference of 2.09 cm³ per year [95% CI: 0.77, 2.96; 
P<0.001]. Comparing non-benign versus benign RRMS, the rate of lesion growth per 
year were 1.08 and 0.66 cm³ respectively, a difference of 0.42 cm³ per year [bootstrap 
95% CI: - 0.01, 0.90; 0.05 < P < 0.07].  
 
To assess if there was a levelling off or alternatively acceleration in lesion growth, a 
quadratic term in time was added to the longitudinal models to test for curvature: 
significant negative or positive quadratic terms indicate, respectively, reducing or 
accelerating rates of growth. However there is less power in any one group to detect 
curvature than to detect a difference in curvature between groups. In the whole group 
there was no evidence of a curved trajectory (bootstrap P > 0.9); nor was there evidence 
at 5% level for curvature in any of the three groups, though the quadratic terms for both 
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the SPMS (with bootstrap 0.1 < P < 0.2) and CIS (bootstrap 0.2 < P < 0.3) subgroups 
were negative, consistent with a levelling off, and positive for RRMS (bootstrap 0.1< P < 
0.2), consistent with accelerated growth. There was a borderline significant decelerating 
curvature in both CIS (bootstrap P = 0.08) and SPMS (bootstrap P = 0.09) compared to 
RRMS. 
 
T2 lesion volumes at all time points were strongly correlated with T2 lesion volume at 20 
years:  T2 lesion volume at baseline vs. 20 years (n = 55, rs = 0.76, P<0.001); 5 year vs. 
20 years (n = 52, rs = 0.83, P<0.001); 10 years vs. 20 years (n = 53, rs = 0.89, P<0.001); 
14 years vs. 20 years (n = 47, rs = 0.94, P<0.001).  
 
For the whole cohort, T2 lesion volume at all time points (0, 5, 10, 14 and 20 years) was 
significantly correlated with 20 year EDSS (rs values 0.48 to 0.67, P < 0.001) and MSFC 
z-scores (rs values [- 0.50] to [-0.61]; P<0.001) (Table 3.5). There were similar 
correlations in those patients who developed clinically definite MS only (Table 3.6).  
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Table 3.5  Correlation of MRI lesion volumes and changes in lesion volumes at various 
time points during the study with disability measured at the 20 year follow up for the 
whole cohort 
 
EDSS MSFC 
P value rs (95% CI) Patients 
Number 
Time  
point 
Patients 
Number 
rs (95% CI) P value 
< 0.001 0.48(0.28-0.64) 73 0 yr 49 -0.49(-0.68 – [-0.24]) 0.0003 
< 0.001 0.62(0.45-0.75) 64 5 yr  48 -0.61(-0.76 – [-0.40]) < 0.001 
< 0.001 0.61(0.43-0.74) 64 0-5 yr 48 -0.56(-0.73 – [-0.33]) < 0.001 
< 0.001 0.55(0.35-0.71) 60 10 yr 50 -0.50(-0.68 – [-0.25]) 0.0002 
0.001 0.45(0.20-0.64) 53 5-10 yr 45 -0.49(-0.68 – [-0.23]) 0.0005 
< 0.001 0.67(0.49-0.80) 53 14 yr  44 -0.59(-0.75 – [-0.36]) < 0.001 
0.004 0.40(0.13-0.61) 48 10-14 yr  42 -0.42(-0.64 – [-0.13]) 0.005 
< 0.001 0.50(0.30-0.65) 74 20 yr 62 -0.53(-0.68 – [-0.33]) < 0.001 
< 0.001 0.49(0.24-0.68) 47 14-20 yr 44 -0.51(-0.70 – [-0.25]) 0.0004 
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Table 3.6  Correlation of MRI lesion volumes and changes in lesion volumes at various 
time points during the study with disability measured at the 20 year follow up for the 
clinically definite MS cohort 
 
EDSS MSFC 
P value rs (95% CI) Patients 
Number 
Time 
point 
Patients 
Number 
rs (95% CI) P value 
0.036 0.31 (0.02-0.55) 46 0 yr 30 -0.41(-0.67 – [-0.06]) 0.024 
<0.001 0.53 (0.27-0.71) 43 5 yr 30 -0.51(-0.73 – [-0.18]) 0.003 
<0.001 0.53 (0.28-0.72) 43 0-5 yr 30 -0.45(-0.70 – [-0.11]) 0.011 
0.005 0.42 (0.13-0.64) 42 10 yr  34 -0.38(-0.63 – (-0.05]) 0.025 
0.026 0.37 (0.05-0.62) 36 5-10 yr  29 -0.39(-0.66 – [-0.03]) 0.033 
<0.001 0.57 (0.30-0.75) 38 14 yr 30 -0.50(-0.73 – [-0.17]) 0.004 
0.020 0.22 (-0.12-0.52) 34 10-14 yr 29 -0.42(-0.68 – [-0.07]) 0.020 
0.009 0.38 (0.10-0.61) 44 20 yr 39 -0.47(-0.69 – [-0.19]) 0.002 
0.003 0.50 (0.18-0.72) 32 14-20 yr 30 -0.54(-0.75 – [-0.22]) 0.002 
 
NB: the larger patient cohort with EDSS measures includes those who had a telephone 
EDSS only 
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For the whole cohort, a significant correlation was found between the change in T2 lesion 
volume over the first 5 years and concurrent change of EDSS (rs = 0.59 [95% CI 0.41-
0.72]; P<0.001). There were significant but weaker concurrent correlations for years 5-10 
and 10-14 and no significant correlation for years 14-20. These correlations were similar 
for those who developed clinically definite MS only (Table 3.7).  
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Table 3.7  Correlations between concurrent changes in MRI lesion volumes and changes 
in EDSS score 
 
All patients Clinically definite MS only 
P value rs (95% CI) Number of 
patients 
Interval Number of 
patients 
rs (95% CI) P value 
< 0.001 0.59 (0.41-0.72) 62 0-5 43 0.69 (0.49-0.82) < 0.001 
0.002 0.40 (0.15-0.60) 53 5-10 36 0.43 (0.12-0.66) 0.008 
0.002 0.41(0.15-0.62) 48 10-14 34 0.46 (0.14-0.69) 0.006 
0.165 0.20 (-0.08-0.46) 47 14-20 32 -0.03 (-0.37-0.31) 0.853 
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Discussion 
This report provides prospectively acquired, longitudinal MRI and clinical data over a 
period averaging 20 years from CIS onset. By comparison, long term follow up of MRI 
findings and clinical course in other CIS cohorts has ranged from 7 to 10 years  (Beck et 
al., 2004; Minneboo et al., 2004; Tintore et al., 2006). The cohort at 20 years has similar 
demographic features to the original cohort in terms of mean age, gender, clinical 
presentation and frequency of baseline MRI abnormalities (Table 3.2). The number of the 
cases ascertained at 20 year follow up was about 50% higher when compared with the 14 
year follow up, and provides a robust long-term assessment of the MRI–clinical 
relationship in relapse-onset MS. The 20 year follow up with clinical and MRI data is the 
longest study of the CIS patients. It also reflects the unmodified natural history of MRI 
lesion load in CIS and MS: only 4/107 patients were treated with disease modifying 
therapies; all 4 after developing clinically definite MS. Other long-term studies have 
often included substantial proportions of patients who received disease modifying 
therapies, which may modify the relationships between MRI and disability (Rudick et al., 
2006a).  
 
Baseline MRI and long-term clinical outcome 
This data confirms and extends the findings of the previous follow up studies of this 
cohort (Brex et al., 2002; Morrissey et al., 1993; O'Riordan et al., 1998c). It shows that 
after 20 years, CIS patients with an abnormal MRI scan at presentation are far more 
likely to convert to clinically definite MS than those with a normal scan (82% versus 
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21%; Table 3.3). It is however noteworthy that 18% of those with an abnormal scan at 
presentation did not develop clinically definite MS. This proportion is higher than that 
reported at 14 year follow up (12%), which likely reflects more complete ascertainment 
of cases in this latest follow up. The detection of such “non-converting” cases after 20 
years (Figure 3.2) supports the approach of the new MS diagnostic criteria that do not 
allow a diagnosis of MS in CIS patients with a single abnormal MRI scan without 
evidence for dissemination in time (Polman et al., 2005). On the other hand it appears 
that the higher risk for MS that is associated with an abnormal scan is evident whether 
there are few or many lesions.  
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Figure 3.2  T2-weighted images of a 49 year old female who had an abnormal baseline 
brain MRI and had remained CIS 20 years later 
 
 
NB: The baseline brain MRI (image on the left) of a patient seen at baseline after CIS 
presentation with optic neuritis showing several hyperintense lesions. The image on the 
right was acquired 20 years later. The scan acquired at 20 years had 12 new hyperintense 
lesions. Despite an abnormal scan this patient did not convert to MS.   
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Brain T2 lesion detection, as several studies have shown, is resolution and slice thickness 
dependent (Bradley & Glenn, 1987; Nielsen et al., 2006; Sicotte et al., 2003). Whilst it is 
possible that with contemporary MR imaging acquiring thinner slices on higher field 
strength magnets, the proportion of people with normal baseline MRI scan  converting to 
MS might be lower than that reported in the present study (21%), recent CIS studies also 
report conversion to MS of patients with a normal brain MRI (Swanton et al., 2007).  
 
The clinically definite MS group in this study exhibited a wide spectrum of disability at 
20 years. Whilst 42% had developed secondary progression, 39% had a benign course 
with minimal disability (EDSS≤3). The percentage of people with benign MS in this 
cohort is higher than that reported on other cohorts of patients (Eriksson et al., 2003; 
Nilsson et al., 2005). Optic neuritis presentation has been associated with better outcome 
in several reports  (Beck et al., 2003; Beck et al., 2004; Confavreux et al., 2003; Nilsson 
et al., 2005) and nearly half of this cohort presented with optic neuritis. However, the rate 
of conversion to clinically definite MS was high (67%) and the 20 year disability status 
of the optic neuritis group did not differ significantly from the non-optic neuritis group, 
so this does not appear to explain the high proportion of minimally disabled MS patients 
in this cohort. However, patients in this cohort were followed up prospectively from their 
first episode, before a diagnosis of MS was established, and efforts were made to follow 
up all patients, whether or not they had developed MS at an earlier time point. Some of 
those with mild/benign MS may not be followed up at a routine MS or general neurology 
clinics and may not be detected in prevalence studies. 
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Patients with a higher number of lesions at baseline were somewhat more likely to be 
disabled after 20 years: an EDSS of 6 or more, indicating that assistance is required for 
walking, was seen in 45% with ≥10 lesions, 35% with 4-9 lesions, 18% with 1-3 lesions 
and 6% with no lesions suggesting that lesion number has some predictive effect for 
disability (Table 3.3).  Conversely, about one third (35%) of patients with ≥10 lesions 
had minimal disability after 20 years (EDSS≤3) and 18% had not developed clinically 
definite MS. Such a wide spectrum of outcomes indicates that MRI lesion number at CIS 
presentation provides limited prediction for long term disability.  
 
MRI lesion volume evolution over 20 years 
This study sheds new light on lesion load evolution and the natural history of CIS and 
MS. The rate of lesion volume growth over 20 years was clearly higher in those 
developing SPMS than in those who retained a relapsing remitting course, and this 
difference became clearly evident 5 years after the first CIS presentation (Figure 1). 
These findings should be investigated in other cohorts of patients with more frequent 
follow ups to determine whether an earlier than 5 year timepoint might show these 
differences (lesion volume measures were not available at the one year follow up in the 
present cohort). Reliable early identification of patients at high risk for secondary 
progression is important: for such individuals there is a high priority to develop disease 
modifying treatments that delay or prevent secondary progression.  
 
Immunomodulatory treatment with beta interferon in CIS patients with abnormal MRI for 
up to over 3 years decreases the number of new MRI lesions, delays development of 
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clinically definite MS (Comi et al., 2001; Jacobs et al., 2000b; Kappos et al., 2006a), and 
possibly slows development of early disability (Kappos et al., 2007).  Whilst this natural 
history cohort data suggests that slowing of lesion volume increase might delay or 
prevent secondary progression, an alternative consideration is that the white matter T2 
lesion volumes seen in this study may have increased in parallel with anatomically and 
mechanistically separate pathological changes that are more directly responsible for long 
term disability e.g. pathology in normal appearing brain white and grey matter or spinal 
cord disease. It is plausible that if a therapy prevents new T2 lesions but not abnormalities 
in normal appearing white and grey matter, secondary progression and disability will still 
evolve. There is a need to investigate the long term relationship of other MRI measures 
that are abnormal in CIS and early relapsing remitting MS (e.g. brain volume and 
quantitative measures of normal appearing white and grey matter (Dalton et al., 2004; 
Fernando et al., 2004; Fernando et al., 2005)) with the long term clinical course both in 
untreated patients and those on disease modifying treatment.  
 
Despite the loss of some subjects to clinical and/or MRI examination and changes in MRI 
technology a robust long term relationship of lesion volume and EDSS was observed, 
albeit of a moderate strength only. The lesion volumes at all time points were correlated 
with the 20 year EDSS suggesting that the moderate predictive value of T2 lesion volume 
appears early in the disease. 
 
Several reasons might explain why brain lesion volume and disability are only 
moderately – rather than strongly – correlated. First, not all patients were followed up 
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with MRI. Secondly, the detection of the T2 hyperintense lesions and lesion load is 
resolution dependent (Erskine et al., 2005; Filippi et al., 1995) and the use of 5mm  thick 
slices (or 10mm in few scans at baseline) will have limited detection of smaller lesions. 
In addition changes in scanner hardware and software (Table 3.1), during the follow up 
period could have had some effect on a lesion measurement precision (earlier 
measurements less sensitive than the later ones). However, it should not have affected the 
relative ranking of patients with regard to lesion volumes, and hence the strength of 
clinical correlations observed. Furthermore there was no evidence of a step increase in T2 
lesion volume between year 5 and 10 when the change in scanner and field strength (from 
0.5 to 1.5 Tesla) occurred. Thirdly, with current  MRI techniques, intra-cortical lesions 
remain largely undetected (Geurts et al., 2005; Kidd et al., 1999). Fourthly, 
demyelinating lesions also occur  in the spinal cord in CIS and MS patients (O'Riordan et 
al., 1998b). It is possible that some patients in this cohort had more severe spinal disease 
with less abnormality in the brain. MS cord pathology may be independent of 
concomitant brain changes, develop at different rates according to the disease phenotypes 
and  be associated to medium-term disability accrual (Agosta et al., 2007). Fifthly, 
despite a high sensitivity to global tissue damage, the T2 lesion volume measure lacks 
pathological specificity – it is collectively sensitive to inflammation, oedema, 
demyelination and axonal loss as well as remyelination and is therefore not specific for 
the irreversible  damage to myelin and axons that underpin irreversible disability in MS 
(Guttmann et al., 1995). Furthermore, lesions occur in semi-random locations which may 
or may not be clinically eloquent. Sixthly, abnormalities in normal appearing white and 
grey matter are also detected early on the disease (Audoin et al., 2006; Fernando et al., 
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2004; Fernando et al., 2005)  and have the potential to influence the clinical course. The 
concurrent correlation between T2 lesion volume and EDSS change was most apparent in 
the first quinquennium and was not present in the fourth and final follow up interval 
(years 14-20) (Table 3.6). This suggests that the mechanisms of disability progression 
may change over time. Disability may be more dependent on lesion volume changes 
earlier on and less dependent later on (Li et al., 2006). The investigation of other MRI 
measures - atrophy, normal appearing white and grey matter and the spinal cord 
abnormality - could explore the hypothesis that they may be more closely related to 
disability changes at a later stage.  
 
Finally, when looking at the associations between lesion volume and disability it is 
important to take into account the limitations of EDSS scale – e.g. intraobserver 
variability, being heavily weighted towards physical disability with limited assessment of 
key clinical features such as cognitive and sphincter dysfunction. In addition, interpreting 
the association between a succession of changes and a later outcome can be difficult for a 
number of reasons. Subjects with large changes during one period often have smaller 
changes over the next period, due to a phenomenon similar to regression to the mean. 
There also may be “ceiling effects”, where subjects with large early changes have less 
room for later changes. The rate of EDSS change in MS is not constant over time, with 
typically longer periods stationed at certain levels (e.g. 3 and 6) than others. Furthermore, 
there were some differences in the patient cohorts studied at the various study time-points 
- it is possible that this has influenced the results. 
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Is the MRI lesion volume increase linear or non-linear? 
This analysis suggests a relatively linear – or constant – increase in lesion volume in MS 
over the 20 years of follow up, whether patients retain a relapsing remitting course or 
develop secondary progression. Further analysis investigating for non-linear changes 
revealed a non-significant trend in secondary progressive patients – who had an overall 3-
fold greater increase in volumes than those who were still relapsing remitting – for the 
rate of lesion volume increase to slow over time. However, unlike the findings in a recent 
cross-sectional study (Li et al., 2006), a definite or complete plateauing of lesion volume 
with the higher levels of disability associated with secondary progression could not be 
detected , at least within the 20 year time frame of the study. Because of their disability, 
proportionately more of the secondary progressive MS patients were not able to undergo 
MRI scans at later time-points and the imaging data at these times reflects a group of 
slightly less disabled patients – whether this contributes to the slight non-linearity is 
uncertain. Future longitudinal studies of larger cohorts may provide clarification.  
 
In summary this long-term follow up study demonstrates that T2 brain lesions have a 
moderate correlation with disability and their predictive value appears early on the 
disease. Lesion load continues to increase for at least 20 years in relapse-onset MS 
patients and the rate of lesion growth in those who develop SPMS is higher than those 
who retain a relapsing-remitting course.  
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PART III 
 
TISSUE SPECIFIC ABNORMALITIES AND THEIR RELATIONSHIP WITH 
DISABILITY IN RELAPSE-ONSET MULTIPLE SCLEROSIS 
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Chapter IV 
Grey matter atrophy is related to long-term disability in multiple sclerosis 
 
Introduction 
As emphasised in earlier chapters, MRI detectable WM lesions are usually seen early in 
relapse onset MS, and in people who develop a CIS suggestive of MS they are associated 
with conversion to clinically definite MS (Polman et al., 2005; Swanton et al., 2007),  
although only predict subsequent disability to a limited degree (Brex et al., 2002). Work 
presented in Chapter 3 also confirmed these findings. 
 
Brain atrophy is also seen from clinical disease onset in MS (Brex et al., 2000); it is 
prominent in the later stages of the disease, and is more marked in SP compared with RR 
phenotypes of MS (Dalton et al., 2006; Miller et al., 2002), although the relative 
influence of disease phenotype and disease duration on such atrophy is uncertain. 
 
From pathological studies extensive cortical damage has been observed predominantly in 
progressive forms of MS, suggesting that GM pathology may be an important 
determinant of irreversible disability (Pirko et al., 2007).  Whilst whole brain atrophy has 
been well explored, the advent of new MRI acquisition and analysis tools now makes it 
possible to determine the relative extent of both GM and WM atrophy. Recent work 
investigating the progression of tissue specific atrophy - measured using methods based 
on Statistical Parametric Mapping (SPM) segmentations -  after first presentation with a 
CIS, showed significantly greater GM compared with WM atrophy in those subjects who 
developed clinically definite MS within three years (Dalton et al., 2004). Furthermore, in 
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people with early RRMS, GM atrophy over 2-years was more rapidly progressive than 
WM atrophy (Tiberio et al., 2005). These studies suggest that progressive GM atrophy 
occurs early in the clinical course of MS, and in the case of CIS, is of direct and 
immediate clinical relevance. Whilst some studies have detected  predominantly GM 
atrophy  (Chard et al., 2002; Dalton et al., 2004; De et al., 2003; Quarantelli et al., 2003; 
Sastre-Garriga et al., 2004) not all have: indeed some observed mostly WM atrophy (Ge 
et al., 2001b)  and it remains to be definitively determined which tissue is most affected 
at any given stage of the disease, particularly in the longer term. 
 
 
The relationship between WM lesions and brain atrophy also remains unclear, with 
current evidence suggesting a partial discordance between these pathological 
manifestations of MS (Anderson et al., 2006) both in cross-sectional and longitudinal 
studies (Chard et al., 2003; Chard et al., 2002; Dalton et al., 2004; De et al., 2003; Ge et 
al., 2000; Paolillo et al., 2000; Rudick et al., 2006a; Sailer et al., 2003). The suggestion 
that there is at least a partial discordance between T2 lesion load (T2LL) and atrophy 
measures during the evolution of MS is supported by the observation that whilst disease-
modifying therapies such as beta interferon are relatively effective in preventing new 
WM lesion formation, their effect in reducing atrophy has been modest (Filippi et al., 
2004; Zivadinov et al., 2007), and in some studies not evident at all (Kappos et al., 
2006b; Molyneux et al., 2000). 
 
With this context, the primary objective of this study was to estimate GM and WM 
volumes in the same cohort of CIS patients followed up 20 years from clinical disease 
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onset (See Chapter 3), and to assess the relationship between these measures of tissue 
specific atrophy, clinical course, and disability, in particular investigating the hypothesis 
that GM atrophy will correlate better with clinical disease severity. Secondary objectives 
were to: (i) evaluate the relationship of GM and WM volumes with T2LL, and (ii) 
investigate the relative contributions of GM and WM volumes and T2LL to disability. 
 
 
Methods 
Subjects 
This report is based on 20 year follow up data of a cohort who had clinical and MRI 
assessments at approximately 5-yearly intervals after presenting with a CIS suggestive of 
MS (Brex et al., 2002) (See Chapter 3). Clinical status was documented at the 20 year 
follow up in 107 patients (Chapter 3), of whom 75 had an MRI examination, with data 
from two patients excluded (one who developed cerebrovascular disease and one who did 
not complete the scanning protocol). The remaining 73 patients are the subject of this 
report.  
 
Clinically definite MS was diagnosed on clinical grounds alone (Poser et al., 1983). 
Disability was assessed using the expanded disability status scale (EDSS) (Kurtzke, 
1983) and MS functional composite scores (MSFC) (Fischer et al., 1999). The clinical 
course of MS (RRMS or SPMS) was defined by Lublin and Reingold criteria (Lublin & 
Reingold, 1996). Those clinically definite MS patients with an EDSS ≤ 3 were defined as 
benign MS. Patients were studied a mean (SD) of 20 (1.5) years, (range 18-27) following 
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the CIS [49 women and 24 men; mean age 51.4 (7.2) years]; 29 were still classified as 
CIS [mean disease duration 20.4 (2.06); mean age 51.5 (8.4) years], 33 had developed 
RRMS [mean disease duration 19.7 (1.1); mean age 51 (6.1) years] and 11 SPMS [mean 
disease duration 19.8 (0.68); mean age 52 (7.3)]. The median EDSS was 2.5 [range 0-8] 
for all patients and 3.25 [range 1-8] for MS patients only. Three patients were on disease 
modifying treatments. MRI was also performed in 25 healthy controls [14 women and 11 
men; mean age 41.7 (7.7) years].  
 
The study was approved by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee. All study participants gave 
written informed consent. 
 
Image acquisitions and processing 
Whole brain MRI was performed on a 1.5 Tesla GE Signa scanner (General Electric, 
Milwaukee, WI) as follows: (1) 2D dual-echo proton density (PD) (TE 17ms) and T2 (TE 
102ms) weighted fast spin-echo (FSE) [repetition time (TR) 2000 ms; 28 × 5 mm slices; 
field of view  24 × 18 cm; in-plane resolution of 1.1 mm]; (2) 3D axial T1-weighted 
inversion-prepared fast spoiled gradient recall  [TR 10.9 ms; TE 4.2 ms; inversion time 
450 ms; 124 × 1.5 mm slices; imaging matrix 256 × 160, interpolated to a final in-plane 
resolution of 1.1 mm]. The identification of lesions on hard copies of the PD-weighted 
images, with reference to the T2-weighted images was performed by myself and checked 
for consistency by an experienced neuroradiologist blinded to the clinical details. This 
was then used as a reference for contouring of the lesions on the PD-weighted digital 
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images, using a semi-automated local thresholding technique implemented in the image 
display package DispImage (Plummer, Department of Medical Physics and 
Bioengineering, University College London) (Sailer et al., 1999) (Fig 4.1). Then, a 
computer program summed all the individual lesion volumes (calculated as surface area 
of each lesion multiplied by slice thickness) and T2LLs were generated.  
 
Segmentation of the axial 3D T1-weighted images into WM, GM and cerebrospinal fluid 
(CSF) was performed using SPM2 (Statistical Parametric Mapping; Wellcome 
Department of Cognitive Neurology, Institute of Neurology, Queen Square, London), 
following a previously described method (Chard et al., 2002) (software available free to 
the research community at www.nmrgroup.ion.ucl.ac.uk/atrophy). The processing 
parameters for SPM2 were set to 0.01 for the bias correction, and 30 for the bias cutoff.  
Briefly, lesion masks, derived from the 3D T1-weighed lesion contours, were subtracted 
from GM, WM and CSF masks using in house software; this yielded 4 mutually 
exclusive tissue masks. From these masks the GM, WM, T1 lesion and CSF volume were 
calculated. WM and GM fraction volumes (WMF and GMF) relative to total intracranial 
volume] were derived, corrected for lesion misclassification as GM (Figure 4.1) (Chard et 
al., 2002). All the tissue masks were inspected, and no significant segmentation errors 
were detected. 
 
To assess the robustness of results obtained using SPM2, I re-processed the data using 
SIENAx (Structural Image Evaluation, using Normalization, of Atrophy for cross-
sectional measurement), a fully automated technique, to obtain the normalized GM and 
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WM volumes (NGMV and NWMV) (Figure 4.2) (Smith et al., 2002). Briefly, SIENAx 
first extracts brain and skull voxels from the input MR data, using the Brain Extraction 
Tool (www.fmrib.ox.ac.uk/fsl). The brain image is then affine-registered to standard 
space brain and skull images, derived from the MNI152 standard space reference set, 
with the skull registration used to determine the head size normalization factor. Next, 
tissue type segmentation, with partial volume estimation, is carried out in order to 
calculate the total volume of brain tissues, including separate estimates of volumes of 
GM, WM and ventricular CSF. The estimated volumes for a subject are then multiplied 
by the normalization factor to obtain NGMV and NWMV (normalized CSF and whole 
brain volumes were also obtained - data not presented here). 
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Figure 4.1  Segmentation of a 3D T1-weighted FSPGR scan into GM, WM and CSF 
mask 
 
Top left – original 3D FSPGR scan; top right – contouring of the hypointense lesions; 
bottom raw – (from left to right) GM, WM and CSF mask. Lesion contouring (top right) 
was done so to correct for lesion misclassification as GM. 
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Figure 4.2  Overlaid GM (red and blue) and WM (green and white) masks using SPM2 
(left) and SIENAx (right) 
 
NB: Lesion mask was used for the SPM2 segmentation (left) to remove lesions – shown 
as black areas within the green WM mask. 
 
 
 
 
 
 
 
 
 
  
 
119
Statistical Analyses 
Group comparisons of the brain tissue volumes were performed using linear regression 
with group indicator and age and gender covariates. To assess the associations between 
the brain volume measurements, T2LL, and disability (EDSS and MSFC and its 
components), Spearman rank correlation was used. 
 
To assess the relative contribution of the WM and GM volume loss and T2LL to accrued 
disability, ordinal logistic regression (for EDSS) and linear regression (for MSFC) were 
used. The predictive value to disability of tissue specific volume measurements obtained 
was assessed separately for each technique (i.e. SPM and SIENAx). Both EDSS 
(categorised as follows: ≤1.5; >1.5 and ≤3; >3 and ≤6; >6) and MSFC (as a continuous 
variable) were modelled as response variables, with tissue volumes, lesion load, age and 
gender as covariate predictors. Lesion load was log transformed to improve Normality 
before inclusion in the regression models; where the T2LL was zero (10 subjects), the log 
volume was given a value of 0.01 to include these subjects. Changing the EDSS category 
intervals, or the small value given for the log volume where the T2LL was zero, did not 
materially change the results. 
 
MRI covariates were entered together and removed singly by manual backwards stepwise 
exclusion until all model predictors were significant at p<0.1. Age and gender were 
added to the final models but omitted if the adjusted coefficients were both non-
significant and not materially different from unadjusted coefficients. Models were 
applied to the whole cohort of patients and the MS subgroup separately. 
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The data were analyzed using SPSS 11 (SPSS Inc, Chicago, IL, USA) and Stata 9.2 
(Stata Corporation, College Station, TX, USA). Statistical significance was taken at 
p<0.05. 
 
Results  
Tissue specific volumes and clinical subgroups: Tables 4.1 & 4.2 for SPM measurements 
& Tables 4.3 & 4.4 for SIENAx measurements. 
 
Using SPM2, tissue specific volumes were significantly lower in MS patients and MS 
subgroups (RRMS and SPMS) versus controls. Significant GM atrophy and WM atrophy 
was seen in MS patients compared with controls. There was significantly more GM 
atrophy, but not WM atrophy, in SPMS versus RRMS and RRMS versus CIS. There was 
significantly greater GM atrophy but, not WM atrophy, in those (non-benign) MS 
patients with an EDSS > 3 (22 patients) compared with those (benign) MS patients with 
an EDSS ≤ 3 (22 patients). There were no significant differences for any of the volume 
measurements between the controls and those remaining classified as a CIS after first 
presentation.  
 
SIENAx yielded similar results consistent with the GMF regarding GM volume 
measurements. For the WM volume measurements, there were no significant differences 
in any group comparison. 
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Table 4.1  Mean and Median (SD) of brain volume measurements using SPM2 
 
Groups 
(Number of patients) 
GMF 
Mean; Median (SD)
WMF 
Mean; Median (SD)
Controls (25) 0.51; 0.52 (0.01) 0.29; 0.29 (0.01) 
All patients (73) 0.49; 0.49 (0.03) 0.28; 0.28 (0.01) 
CIS (29) 0.50; 0.50 (0.02) 0.28; 0.28 (0.01) 
MS (44) 0.47; 0.48 (0.03) 0.28; 0.28 (0.01) 
RRMS (33) 0.48; 0.49 (0.02) 0.28; 0.28 (0.01) 
Benign MS (22) 0.49; 0.49 (0.02) 0.28; 0.28 (0.01) 
Non-benign MS (22) 0.46; 0.46 (0.03) 0.28; 0.27 (0.01) 
SPMS (11) 0.45; 0.45 (0.03) 0.27; 0.27 (0.01) 
 
 
CIS = Clinically isolated syndrome; MS = Multiple sclerosis (RRMS and SPMS); RRMS 
= Relapsing-remitting MS; SPMS = Secondary progressive MS; GMF = Grey matter 
fraction; WMF = White matter fraction; Benign MS = EDSS ≤ 3; Non-benign MS = 
EDSS > 3 
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Table 4.2  Age and gender-adjusted mean difference between patient subgroups and 
controls 
 
GMF WMF 
Group 
comparisons 
Adjusted mean difference
95% CI 
p-value Adjusted mean difference
95% CI 
p-value 
MS-Controls -0.027 [-0.041- (-0.014)] <0.001 -0.009 [-0.017 – (-0.001)] 0.017 
MS-CIS -0.028 [-0.039 – (-0.017)] <0.001 -0.003 [-0.010 – 0.003] 0.318 
SPMS-Controls -0.046 [-0.063 – (-0.028)] <0.001 -0.013 [-0.024 – (-0.002)] 0.018 
RRMS-Controls -0.021 [-0.035 – (-0.008)]   0.002 -0.008 [-0.017 – (-0.001)] 0.042 
SPMS-CIS -0.046 [-0.062 – (-0.030)]   0.001 -0.006 [-0.016 – 0.003] 0.179 
RRMS-CIS -0.022 [-0.033 – (-0.010)] <0.001 -0.002 [-0.009 – 0.004] 0.540 
SPMS-RRMS -0.024 [-0.040 – (-0.008)]   0.003 -0.004 [-0.014 – 0.005] 0.361 
Benign-Non- 
benign MS 
0.022 [0.004 – 0.040]   0.01 0.004 [-0.004 – 0.013] 0.328 
CIS-Controls 0.001 [-0.013 – 0.015]   0.089 -0.006 [-0.015 – 0.002] 0.142 
  
NB: Bold - significant at p < 0.05; CIS = Clinically isolated syndrome; MS = Multiple 
sclerosis (RRMS and SPMS); RRMS = Relapsing-remitting MS; SPMS = Secondary 
progressive MS; GMF = Grey matter fraction; WMF = White matter fraction; Benign MS 
= EDSS ≤ 3; Non benign MS = EDSS > 3 
 
 
 
  
 
123
Table 4.3  Normalized brain volume measurements in controls and clinical subgroups 
 
Groups 
(Number of patients) 
 
NGMV 
Mean (cc); Median (SD) 
NWMV 
Mean (cc); Median (SD) 
Controls (25) 910; 916 (40.4) 663; 669 (33.0) 
CIS (29) 885; 888 (40.8) 658; 657 (36.0) 
All patients (73) 858; 870 (60.7) 653; 652 (35.4) 
CDMS (44) 840; 853 (65.4) 650; 649 (35.0) 
RRMS (22) 856; 865 (60.4) 649; 649 (33.7) 
Benign MS (22) 874; 885 (61.8) 659; 660 (31.0) 
Non-benign MS (22) 806; 798 (50.3) 640; 643 (36.8) 
SPMS (11) 795; 793 (61.3) 652; 646 (40.6) 
 
CIS = Clinically isolated syndrome; CDMS = Clinically definite multiple sclerosis; 
RRMS = Relapsing-remitting MS; SPMS = Secondary progressive MS; NGMV = 
Normalized gray matter volume; NWMV = Normalized white matter volume; Benign 
MS = EDSS ≤ 3; Non-benign MS = EDSS > 3 
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Table 4.4  Adjusted mean difference between patient subgroups & controls using 
SIENAx 
 
NGMV NWMV 
Group 
comparisons 
Adjusted mean difference 
(cc) 
95% CI 
p-value Adjusted mean difference
(cc) 
95% CI 
p-value 
MS-Controls -56.52 [-85.05 - (-27.99)] 
 
<0.001 -14.11 [-33.99 - 5.76] 
 
0.162 
MS-CIS -47.60 [-71.64 – (-23.57)] 
 
<0.001 -8.62 [-25.37 - 8.11] 
 
0.309 
SPMS-Controls -96.63 [-133.91 – (-59.35)] 
 
<0.001 -11.12 [-38.43 - 16.17] 
 
0.420 
RRMS-Controls -43.49 [-71.98 – (-15.00)] 
 
  0.003 -15.08 [35.95 - 5.78] 
 
0.155 
SPMS-CIS -87.06 [-121.02 – (-53.11)] 
 
<0.001 -5.68 [-30.55 - 19.18] 
 
0.651 
RRMS-CIS -33.92 [-58.48 – (-9.37)]   0.007 -9.64 [27.63 - 8.33] 
 
0.290 
SPMS-RRMS -53.14 [-86.08 – (-19.47)] 
 
  0.002 3.95 [-20.70 - 28.62] 
 
0.751 
Benign-Non 
benign MS 
65.25 [30.05 – 100.44] 0.001 17.69 [-3.30 – 38.70] 0.09 
CIS-Controls -8.91 [-39.51 - 21.68] 
 
  0.564 -5.48 [-26.80 - 15.82] 
 
0.610 
 
NB: Bold - significant at p < 0.05; MS = Multiple sclerosis (all cases); CIS = Clinically 
isolated syndrome; RRMS = Relapsing-remitting MS; SPMS = Secondary progressive 
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MS; NGMV = Normalized gray matter volume; NWMV = Normalized white matter 
volume; Benign MS = EDSS ≤ 3; Non benign MS = EDSS > 3 
 
MRI measures and disability Table 4.5 
GMF correlated significantly with EDSS and MSFC for all patients and for the MS 
subgroup alone. WMF showed no such correlations. T2LL also correlated with EDSS (rs 
= 0.49; p<0.001) and MSFC (rs = -0.53; p<0.001) for all patients as well as in the MS 
subgroup: (rs = 0.38; p = 0.009) and (rs = -0.43; p=0.005) respectively. Correlations of 
SIENAx measurements with clinical features are presented in Table 4.6. 
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Table 4.5  Correlations of brain volume measurements with clinical features  
 
EDSS 
N=73* (44§) 
MSFC 
N=67* (41§) 
Z-PEG 
N=70* (42§) 
Z-WALK 
N=68* (40§) 
Z-PASAT 
N=68* (42§) 
 
rs (p-value) 
GMF* -0.48 (<0.001) 0.56 (<0.001) 0.59 (<0.001) -0.40 (0.001) 0.27 (0.026) 
GMF§ -0.41 (0.005) 0.55 (<0.001) 0.44 (0.003) -0.49 (0.001) 0.32 (0.038) 
WMF* -0.20 (0.086) 0.03 (0.784) 0.16 (0.176) -0.11 (0.337) -0.07 (0.537) 
WMF§ -0.11 (0.443) 0.10 (0.526) 0.28 (0.071) -0.09 (0.560) -0.04 (0.761) 
 
* All patients 
§ MS subgroup only 
Bold: significant at p < 0.05; rs = Spearman Rank correlation coefficient; GMF = Grey 
matter fraction; WMF = White matter fraction; EDSS = Expanded disability status scale; 
MSFC = Multiple sclerosis functional composite score 
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Table 4.6 Correlations of SIENAx brain volume measurements with clinical features  
 
EDSS 
N=*73(§44) 
MSFC 
N=*62(§39) 
Z-PEG 
N=*62(§39) 
Z-WALK 
N=*62(§39) 
Z-PASAT 
N=*62(§39) 
 
 
rs (p-value) 
*NGMV -0.62 (<0.001) 0.49 (<0.001) 0.62 (<0.001) -0.34 (0.006) 0.19 (0.12) 
 
§NGMV -0.53 (<0.001) 0.39 (0.01) 0.54 (<0.001) -0.45 (0.005) 0.14 (0.38) 
 
*NWMV -0.31 (0.006) 0.15 (0.24) 0.12 (0.33) -0.29 (0.02) 0.18 (0.15) 
 
§NWMV -0.28 (0.05) 0.14 (0.39) 0.24 (0.12) -0.19 (0.24) 0.21 (0.19) 
 
 
* All patients 
§ CDMS patients only 
Bold: significant at p < 0.05; rs = Spearman Rank correlation coefficient; CIS = Clinically 
isolated syndrome; CDMS = Clinically definite multiple sclerosis (all cases); RRMS = 
Relapsing-remitting MS; SPMS = Secondary progressive MS; NGMV = Normalized 
grey matter volume; NWMV = Normalized white matter volume 
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Correlations of lesions with grey and white matter volumes 
T2LL correlated significantly with GMF (rs = -0.63; p<0.001) but not with WMF (rs = -
0.15; p = 0.19) for the whole cohort of patients and for the MS subgroup only: (rs = -0.66; 
p<0.001) and (rs = -0.18; p = 0.22) respectively. 
T2LL correlated significantly with NGMV (rs = -0.57; p<0.001) but not with NWMV (rs = 
-0.14; p = 0.22) for all patients and for the MS subgroup only: (rs = -0.67; p<0.001) and 
(rs = -0.10; p = 0.50) respectively. 
 
 
Predicting Disability 
For the whole cohort of patients, only GMF predicted EDSS category: there was an 
estimated 68% (p<0.001) reduction in the odds of having greater disability per 1 SD 
higher GMF. 
GMF only also, independently predicted disability as measured by MSFC scores; there 
was an estimated 0.62 increase (p<0.001) in MSFC per 1 SD higher GMF. 
 
Restricting regression models to the MS subgroup of patients, only GMF independently 
predicted disability, whether EDSS or MSFC:  there was a 59% (p = 0.007) reduction in 
the odds of being in more severe EDSS category per 1 SD higher GMF; and there was a 
0.67 increase (p = 0.001) in MSFC per 1 SD higher GMF. 
 
On the regression models using SIENAx measurements, only NGMV independently 
predicted disability whether EDSS or MSFC, on the whole cohort of patients and on the 
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MS subgroup only. For the whole cohort of patients there was a 79% (p<0.001) reduction 
in odds of being in a more severe EDSS category per 1 SD higher NGMV; and there was 
a 0.54 increase (p<0.001) in MSFC per 1 SD higher NGMV. 
In the MS subgroup, there was a 71% (p = 0.001) reduction in odds of being in a more 
severe EDSS category per 1 SD higher NGMV; and there was a 0.52 increase (p = 0.010) 
in MSFC per 1 SD higher NGMV. 
 
The independent MRI predictors of the MSFC components for the SPM2 and SIENAx 
measurements separately, for all patients and MS group only are presented in Table 4.7. 
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Table 4.7  Independent MRI predictors of MSFC components in regression models  
 
SPM2 (p-value) SIENAx (p-value)  
All patients CDMS only All patients CDMS only 
9HPT 
(N=70/42) 
GMF (<0.001) 
 
T2LL (<0.001) 
Age (0.006) 
Gender (0.056) 
 
NGMV (<0.001) 
T2LL (0.029) 
Age (0.031) 
 
NGMV (0.014) 
T2LL (0.013) 
Age (0.006) 
 
ITW 
(N=68/40) 
GMF (<0.001) 
Age (0.002) 
GMF (<0.001) 
Age (0.032) 
NGMV (<0.001) 
Age (0.019) 
Gender (0.001) 
 
NGMV (<0.001) 
Age (0.003) 
Gender (0.023) 
 
PASAT 
(N=68/42) 
GMF (0.024) None None None 
 
N = number of patients shown – all patients/CDMS 
MSFC = Multiple Sclerosis Functional Score; CDMS = Clinically definitive MS; SPM2 
= Statistical parametric mapping; SIENAx = Structural Image Evaluation, using 
Normalization, of Atrophy for cross-sectional measurement; GMF = Grey matter fraction 
WMF = White matter fraction; NGMV = Normalised GM volume; NWMV = 
Normalized WM volume; 9HPT = 9 Hole peg test; PASAT = Paced auditory serial 
additional test; T2LL = T2-weighted lesion load; ITW = Inverted timed walk 
 
  
 
131
Discussion  
This study builds on previous work (Carone et al., 2006; Chard et al., 2003; Sanfilipo et 
al., 2005), characterising tissue specific brain atrophy in a group of people with MS or 
CIS who have a uniquely long and homogeneous disease duration (~20 years). It has 
allowed an exploration of the associations and role as predictors of MRI measures - tissue 
specific (GM and WM) atrophy and (WM) lesion load - with clinical phenotype and 
disability, relatively free of confounding by variability in disease duration. 
 
In this cohort of  patients both GM and WM atrophy was seen in MS patients compared 
with controls, and the extent of GM atrophy was greater than that of WM atrophy in 
keeping with some previous studies  (Chard et al., 2002; Dalton et al., 2004; De et al., 
2003; Quarantelli et al., 2003; Sastre-Garriga et al., 2004). Furthermore, there was 
significantly more GM, but not WM, atrophy in SPMS versus RRMS, and RRMS versus 
those remaining CIS patients. It should be noted that GM atrophy has not been a 
universal finding in MS, and that a definitive consensus on the location and timing of 
brain atrophy has yet to be reached; however a significant number of recent studies 
suggest that GM atrophy is a consistent finding throughout the clinical course of MS, 
seemingly mirroring clinical status  (Dalton et al., 2004; Sanfilipo et al., 2005; Sastre-
Garriga et al., 2005; Tiberio et al., 2005). The apparent discrepancy in some previous 
studies may represent a combination of cohort related and technical factors. Although 
there is no universally accepted gold-standard method for measuring GM and WM 
volumes, the SPM-based approach has provided consistent findings in several previous 
studies  (Chard et al., 2002; Dalton et al., 2004; Sanfilipo et al., 2005; Tiberio et al., 
  
 
132
2005), and in the present study, the robustness of the results obtained using SPM-based 
methods have been consolidated by very similar findings with another widely used 
segmentation method - SIENAx.  
 
Given the relatively homogeneous disease duration and age distribution of the clinical 
subgroups included in the present work, the association of GM atrophy with clinical 
status is not explained by these factors; rather, the findings suggest a direct link between 
GM atrophy and clinical disease severity.  
 
Differential tissue specific atrophy in MS may be partially explained by variable degrees 
of inflammatory activity in WM and GM (Bo et al., 2003; Peterson et al., 2001), with 
relatively greater compensation of cell loss by inflammatory infiltrates and oedema in 
WM compared with GM. Differential inflammatory noise in the volumetric measures 
may also lead to greater attenuation of  WM compared with GM associations with 
clinical parameters. However, it may be expected that eventually atrophy, if progressive, 
would reach a magnitude where it would no longer be disguised by inflammatory 
interference; given this, my observations in MS patients with relatively long disease 
duration suggest that WM atrophy is truly less progressive than that of GM, and not 
simply the result of compensation by, and short-term fluctuations associated with, 
inflammation. In addition, whilst no clear evidence of an association between WM 
atrophy and disability was detected, 50% of MS patients in the present cohort had a 
benign clinical course, and it is conceivable that larger cohort with more severe disability 
(e.g. EDSS 7 and higher) might exhibit more WM atrophy; further work is required to 
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explore this possibility. Considered overall, these findings suggest that measures of GM 
atrophy will be more useful than WM volume in natural history studies or treatment 
trials, for example in a study of potentially neuroprotective agents, although serial studies 
should further investigate the relationship between longitudinal GM volume and clinical 
changes. A recent longitudinal study of MS patients by Fisher et al, showed that the GM 
atrophy rate, but not WM atrophy rate – which was constant across MS subtypes, 
increased with disease severity: from 3.4 fold normal in CIS patients converting to 
RRMS to 14 fold normal in SPMS (Fisher et al., 2008).  
 
GM, but not WM volume measurements, correlated with clinical disability (EDSS, 
MSFC and its components). Although T2LL correlated significantly with disability, GMF 
was a better predictor of disability when included in the regression models. Whilst noting 
the caveats about inflammatory noise discussed previously, these data suggest that GM 
atrophy has more clinical relevance in the long term than either lesion load or WM 
atrophy in people with MS, being more closely related to long term disability and clinical 
course. The present study findings consolidate and extend the observation made in 
several previous studies that MRI markers of GM involvement correlate more strongly 
with measures of physical disability than WM lesion load (Carone et al., 2006; Fisher et 
al., 2008; Pirko et al., 2007; Sanfilipo et al., 2005; Sanfilipo et al., 2006) .  
The amount of tissue loss in MS probably represents a balance between several 
pathological processes: irreversible neuronal and axonal loss, myelin loss, and reversible 
neuro-axonal atrophy, on the one hand; with partial compensation by inflammation 
associated cellular infiltrates, and cellular [including axonal (Fisher et al., 2007)] and 
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interstitial oedema on the other. With regard to the mechanisms of brain atrophy, there 
may be: (i) antegrade and retrograde neuroaxonal tract degeneration associated with focal 
WM inflammatory lesions (Trapp et al., 1998), with a potentially significant delay 
between axonal demyelination and subsequent neuroaxonal degeneration, and (ii) a more 
widespread process directly targeting neurons, myelin [including cortical demyelination 
(Bo et al., 2003; Peterson et al., 2001)] and glia. 
 
GM (but not WM) volume measurements correlated with WM lesion load, which is in 
keeping with other studies (Chard et al., 2002; Dalton et al., 2004; Sanfilipo et al., 2005; 
Tiberio et al., 2005). This correlation might reflect secondary degeneration from WM 
lesions to GM. That the degree of correlation is only moderate suggests that processes 
independent of WM lesions are also contributing to GM atrophy in MS. One such 
explanation might be GM demyelinating lesions that - although not visible on 
conventional MRI - are commonly found at autopsy (Bo et al., 2003; Peterson et al., 
2001). Our findings emphasise that further research to elucidate pathogenic mechanisms 
in MS should focus on GM as well as WM pathology. 
 
In this study SIENAx and SPM-based methods generally provided similar results when 
investigating the relationship of GM and WM volumes with clinical course, clinical 
features and T2LL. However, WM segmentation obtained by SIENAx appeared to be less 
accurate compared with SPM2,  as deep GM was not as clearly segmented, and 
misclassification of WM lesions was not adjusted for, perhaps explaining why there were 
no differences between the NWMV (derived from SIENAx) between MS patients and 
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controls, while differences were seen in WMF (derived from SPM2). Nevertheless, taken 
the findings reinforced the conclusion that GM pathology is a significant contributing 
factor to the clinical course in relapse onset MS. 
 
When considering the significance of the findings observed in this study it is important to 
take into account a few limitations. Firstly, neither WM lesion volume nor tissue specific 
brain atrophy measurement is pathologically specific. WM lesions on T2-weighted MRI 
may contain variable amounts of inflammation, demyelination, oedema and axonal loss. 
The brain volume measurements, while affected by the same factors, are thought to be 
more specifically weighted towards neurodegeneration. Secondly, the brain volume 
measurement data is cross-sectional, and does not provide any direct information on the 
temporal evolution of atrophy, information which can only be gathered using serial MRI 
data. Hence, one cannot determine whether the atrophy observed in this study occurred 
immediately before, or many years prior to, this study. Although the patients were 
scanned at earlier time-points (Brex et al., 2002), there has been a major scanner 
hardware upgrade since then, rendering it difficult to directly compare measurements 
from earlier scanning with that obtained at 20-years.  Thirdly, some of the more disabled 
patients were not able to be scanned, so this data is relatively biased towards a less 
disabled subset of the patients presented in chapter 3. Fourthly, spinal cord involvement 
makes an important contribution to locomotor disability in MS and was not included in 
this investigation. Finally, with the SPM based methods, misclassification of lesions or 
non brain tissue as GM may lead to a relative underestimation of the apparent magnitude 
of GM disease effects; however, correction for lesion misclassification was performed 
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and quality assurance review of the scans found no additional significant segmentation 
errors – thus, there should not have been significant misclassification effects.  
 
Notwithstanding these caveats, the study clearly found that in MS patients with a 
relatively long and homogeneous disease duration (~20 years), GM atrophy is greater 
than WM atrophy, and reflects disease subtype and disability. It also helps to understand 
why a limited relationship between (WM) lesions and disability in MS has been evident 
in many previous MRI-clinical studies of both natural history and therapeutic 
intervention, and highlights a need to better understand and monitor GM pathology in 
MS. 
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Chapter V 
Magnetisation transfer ratio abnormalities reflect clinically relevant grey matter 
damage in multiple sclerosis 
Introduction  
In multiple sclerosis (MS), the relationship between the white matter (WM) lesion load,  
as assessed using conventional MRI, and disability is only moderate  (Brex et al., 
2002)(see chapter 3). This has prompted a search for other MRI markers of disease 
progression that may either better explain clinical outcomes, or provide additional 
clinically relevant information. A variety of MRI techniques have been developed and, of 
these, brain atrophy measures and magnetization transfer ratio (MTR) have shown 
particular promise in MS, in particular tissue specific estimates of the grey matter (GM) 
damage. GM atrophy, more so than WM lesion accrual or WM atrophy, maybe 
associated with long term disability (Fisher et al., 2008; Pirko et al., 2007). These 
findings were also confirmed in the study presented in Chapter 4. MTR changes in the 
GM especially in early relapsing-remitting MS (RRMS) and primary progressive MS, 
have shown promise as predictors of future disability (Agosta et al., 2006; Khaleeli et al., 
2007a).  
 
Whilst recent histopathological studies in MS have reported extensive cortical 
demyelination (Bo et al., 2003; Gilmore et al., 2008; Kutzelnigg et al., 2005; Moll et al., 
2008) (including deep GM nuclei (Cifelli et al., 2002; Gilmore et al., 2008; Huitinga et 
al., 2004; Vercellino et al., 2005)), a study in an experimental model of MS found no 
clear association between regional cortical demyelination and atrophy (Pomeroy et al., 
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2008). This suggests that some elements of intrinsic cortical damage in MS may be at 
least partly independent of tissue atrophy, or may proceed it (Khaleeli et al., 2007a), and 
that assessment of both may provide complementary information. It is this that is 
explored in this work, using tissue specific MTR as a measure of intrinsic tissue damage 
(Mottershead et al., 2003; Schmierer et al., 2004; van Waesberghe et al., 1999), alongside 
tissue specific volumetric measures to assess atrophy (see Chapter 4). MTR imaging has 
proven a sensitive marker of tissue damage in MS  and, at least in the WM, appears to be 
mainly influenced by demyelination and axonal loss (Dousset et al., 1992; Schmierer et 
al., 2004) and to a lesser degree by inflammation (Dousset et al., 1992; Schmierer et al., 
2007), although pathological features other than demyelination may also be important in 
the determinants of the MTR (Gareau et al., 2000). MTR abnormalities within normal-
appearing (NA)WM and GM have been detected from the earliest clinical stages of MS  
(Audoin et al., 2004; Davies et al., 2004; Fernando et al., 2005), and may increase over 
time (Fisher et al., 2008; Rovaris et al., 2003). Several studies have reported that MTR 
changes in NAWM and GM may differ between clinical subgroups and are correlated 
with disability (Agosta et al., 2006; Ge et al., 2001a; Khaleeli et al., 2007b; Ramio-
Torrenta et al., 2006; Rovaris et al., 2003; Santos et al., 2002; Zivadinov et al., 2001). 
 
By studying a cohort of patients with a long and homogenous disease duration since their 
first presentation with a clinically isolated syndrome (CIS) suggestive of MS, this work 
aimed to: 
 i. Assess how GM and NAWM MTR metrics at 20 years reflect disease subtype 
 (CIS, RRMS or secondary progressive MS (SPMS)) and their level of disability; 
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 ii. Evaluate the relative clinical relevance of the MTR histogram metrics, tissue 
specific brain atrophy estimates, and WM lesion load measures. 
 
Methods  
Subjects 
The patients included in this study are part of a previously described cohort of CIS 
patients followed up approximately every five years for 20 years since their first 
presentation with a CIS suggestive of MS (Chapter 3 & 4). In seventy-five out of 107 
patients seen at 20 years clinical and MRI data were acquired. Six patients were excluded 
(one patient developed cerebro-vascular disease in addition to MS; 2 patients did not 
complete the full scanning protocol and the GM-WM segmentation failed in 3 patients). 
The remaining 69 patients were included in this study [45 female and 24 male; mean age 
51.4 years, range (39.4 - 67.5)]. Twenty eight subjects had remained CIS and 41 had 
converted to clinically definite MS (Poser et al., 1983) (31 had RRMS and 10 had 
evolved to SPMS)(Lublin & Reingold, 1996). Patients  were followed up a mean of  20.0 
years (range 18 – 27) from their first episode of CIS  suggestive of MS. Clinical measures 
included Expanded Disability Status Scale score (EDSS) (Kurtzke, 1983) and MS 
functional composite scores (MSFC) (Fischer et al., 1999). Only two patients were on 
disease modifying treatment and both had RRMS. MRI data was also obtained in 19 
healthy controls [11 females and 8 male; mean age 39.91 (6.53) years, range (30.57 – 
57.30)]. 
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The study was approved by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee. All study participants gave 
written informed consent. 
 
Image Acquisitions and Processing 
The following whole brain sequences were acquired in all subjects at the 20 year follow 
up time-point, using a 1.5 Tesla GE Signa scanner (General Electric, Milwaukee, WI, 
USA): i) 2D interleaved dual spin echo (SE) [repetition time (TR) 1720 ms; echo times 
(TE)s 30/80 ms); 28 × 5 mm slices; matrix 256 × 256; field of view 24 × 24 cm2 ]. Both 
echoes were acquired with and without a MT pre-saturation pulse to calculate a MTR 
map (Barker et al., 1996). The saturating MT pulse was 1 kHz off-water resonance with 
an on-resonance equivalent flip angle of 1430°; ii) 2D dual-echo proton density (TE 
17ms) and T2 (TE 103ms) weighted fast SE [TR 2000 ms; 28 × 5 mm slices; field of 
view  24 × 18 cm2; in-plane resolution of 1.1 mm];  iii) 3D axial T1-weighted inversion-
prepared fast spoiled gradient recall  [TR 10.9 ms; TE 4.2 ms; inversion time 450 ms; 124 
× 1.5 mm slices; imaging matrix 256 × 160, interpolated to a final in-plane resolution of 
1.1 mm; flip angle 20º]. 
 
The long TE images of sequences (i) and (ii) were co-registered using FLIRT 
(www.fmrib.ox.ac.uk/fsl/), and the same transformation was applied to the short echo 
images. Lesions were outlined using a semi-automated method as previously described 
(Sailer et al., 1999). T2 lesion volumes (T2LL) were obtained using the proton density-
weighted scans (short echo) of sequence (ii) and 3D T1-weighted lesion load was 
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computed from sequence (iii). SPM2 www.nmrgroup.ion.ucl.ac.uk/atrophy (Ashburner & 
Friston, 2005) was used to segment the long echo images from sequence (i) into GM, 
WM (both NAWM and lesions) and CSF. (In the three cases where segmentation failed 
the T2LL was very large, which is the reason for the failure). These segmentations were 
combined to obtain WM, GM, and whole brain masks. Lesions were then removed to 
obtain NAWM and GM masks which were applied to the calculated MTR maps. A 10 
percentage unit (pu) lower threshold was applied as were two successive erosions of WM 
and a single erosion of the GM to minimise partial volume effects. Brain volume 
normalized NAWM and GM histograms were generated with a bin width of 0.1 pu and a 
smoothing window of +/- 0.3pu. The peak height (PH), peak location (PL) and mean 
MTR were extracted for NAWM and GM.  
 
WM, GM and brain parenchymal fraction (WMF, GMF and BPF) were obtained from 
sequence (iii) using SPM2 (Wellcome Department of Cognitive Neurology, London, 
UK), corrected for lesion misclassification as GM (Chard et al., 2002) (see Chapter 4). 
 
Statistical Analyses 
Z-scores for MSFC subtests were calculated using the same sample of patients as a 
reference and used to derive MSFC scores (Cutter et al., 1999). 
Cross-sectional group comparisons of the MTR parameters were performed using linear 
regression with group indicator, and age, gender and BPF as covariates. To assess the 
associations between the MTR histogram parameters and T2LL, brain volume 
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measurements and clinical outcomes, due to non-Normality of the variables as was 
shown by normal probability plots, Spearman’s rank correlation was used.  
To assess the relative contribution of the MTR histogram parameters, tissue specific brain 
volumes and T2LL to accrued disability: (i) ordinal logistic regression was used for 
EDSS, categorised as follows: ≤1.5; >1.5 and ≤3; >3 and ≤6; >6, and (ii) linear regression 
was used for MSFC and its components: 9 hole peg test (9HPT); Paced Auditory Serial 
Addition test (PASAT) and timed walk (the inverse of timed walk was used as it was 
more normally distributed). EDSS and MSFC (and its components) were modelled as 
response variables, with MTR parameters, tissue volumes, lesion load, age and gender as 
covariate predictors. Lesion load was log transformed to improve normality before 
inclusion in the regression models. Where the T2LL was zero (10 subjects), the log 
volume was given a value of 0.01 to include these subjects.  
 
For each response variable, MRI covariates were entered together and removed singly by 
manual backwards stepwise exclusion until all model predictors were significant at p<0.1 
(a less stringent p-value threshold was used to take a more conservative approach in 
detecting potential confounds). To minimize the number of model covariates, a multi-
stage approach was used. First, GM and NAWM MTR histogram parameters were 
modelled separately and then the best predictors from the two (GM and NAWM) models 
combined to obtain the best overall MTR model. After establishing the best MTR 
predictors, T2LL and tissue volume (GMF and WMF) measurement were added to obtain 
a final model. Age and gender were added to the final models but omitted if the adjusted 
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coefficients were both non-significant and not materially different from unadjusted 
coefficients.  
 
The data were analyzed using Stata 9.2 (Stata Corporation, College Station, TX, USA). 
Statistical significance was taken at p<0.05. 
 
Results  
The median EDSS for all patients (MS patients and those who had remained CIS) was 2.5 
(range 0-8) and for MS patients only, 3.0 (range 1-8). 
 
Group comparisons 
The mean, median and standard deviation (SD) of the GM and NAWM MTR histogram 
metrics for all patients and healthy subjects are presented in Table 5.1. 
 
Group comparisons are presented in Table 5.2 and Figure 5.1. When age and gender were 
included as covariates, GM PH was found to be significantly lower in: (i) MS patients 
(SPMS and RRMS) versus controls; (ii) SPMS and RRMS versus those subjects 
remaining CIS and (iii) SPMS versus RRMS. In the NAWM, mean MTR and PL were 
significantly lower in: (i) MS patients (SPMS and RRMS) versus controls; (ii) SPMS and 
RRMS versus those subjects remaining CIS, but not between (iii) SPMS versus RRMS. 
WM PH was lower in SPMS compared to all other groups. There were no differences 
between controls and those remaining CIS in any MTR metrics.  
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Table 5.1  Mean and median (Standard Deviation) of the MTR histogram metrics  
 
Mean; Median (SD) 
MS (N = 41) 
 
MTR histogram metrics Controls 
N = 19 
CIS 
N = 25 RRMS 
N = 31 
SPMS 
N = 10 
All patients
N = 69 
Mean MTR (pu) 32.65; 
32.66 (0.44) 
32.41; 
32.34 (0.55) 
32.30; 
32.27 (0.82) 
31.83; 
31.63 (0.82) 
32.27; 
32.27 (0.74) 
PL MTR (pu) 33.31; 
33.40 (0.37) 
33.29; 
33.40 (0.30) 
33.68; 
33.50 (0.99) 
33.37;  
33.25 (1.00) 
33.48; 
33.50 (0.80) 
 
 
GM 
PH % volume/pu 12.10; 
12.54 (1.20) 
11.27; 
11.15 (1.24) 
10.64; 
10.60 (0.99) 
9.24; 
8.86 (1.49) 
10.69; 
10.73 (1.33) 
Mean MTR (pu) 
 
38.56; 
38.52 (0.38) 
38.49; 
38.56 (0.41) 
37.99; 
38.24 (0.91) 
37.77; 
37.90 (0.84) 
38.16; 
38.35 (0.78) 
PL MTR (pu) 
 
38.71; 
38.80 (0.38) 
38.66; 
38.70 (0.52) 
38.25; 
38.50 (0.78) 
38.00; 
38.25 (0.69) 
38.38; 
38.50 (0.70) 
 
 
NAWM 
PH % volume/pu 
 
19.62; 
19.86 (2.28) 
18.84; 
18.85 (1.75) 
19.01; 
19.30 (1.80) 
16.8; 
17.87 (3.17) 
18.63; 
19.18 (2.12) 
 
N = number of subjects shown; CIS = Clinically isolated syndrome; MS = Multiple 
sclerosis; GM = Grey Matter; NAWM = Normal appearing white matter; MTR = 
Magnetization transfer ratio; PL = Peak location; PH = Peak height; pu = Percentage unit 
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Table 5.2  Age- and sex-adjusted mean difference (with p-values in brackets) [95% CI] 
of the MTR histogram metrics between patient subgroups and control subjects  
 
GM NAWM Subgroups 
Mean  
[pu] 
PL  
[pu] 
PH 
% volume/pu
Mean  
  [pu] 
PL  
[pu] 
PH 
% volume/pu
MS – Controls -0.27 (0.205) 
[-0.71 to 0.15] 
0.47 (0.049)* 
[0.002 to 0.94] 
-0.92 (0.009)** 
[-1.60 to -0.24] 
-0.65 (0.005)** 
[-1.10 to -0.19] 
-0.47 (0.027)* 
[-0.89 to -0.05] 
-0.55 (0.350) 
[-1.73 to 0.62] 
CIS – Controls -0.03 (0.861) 
[-0.48 to 0.40] 
0.16 (0.499) 
[-0.32 to 0.65] 
0.05 (0.876) 
[-0.64 to 0.75] 
-0.09 (0.694) 
[-0.56 to 0.37] 
-0.002 (0.992) 
[-0.43 to 0.42] 
-0.07 (0.896) 
[-1.29 to 1.13] 
MS – CIS -0.23 (0.141) 
[-0.55 to 0.08] 
0.30 (0.082) 
[-0.03 to 0.65] 
-0.97 (<0.001)** 
[-1.48 to -0.47] 
-0.55 (0.001)** 
[-0.89 to -0.22] 
-0.47 (0.003)** 
[-0.77 to -0.16] 
-0.47 (0.278) 
[-1.34 to 0.39] 
SPMS – Controls -0.55 (0.054)^ 
[-1.11 to 0.01] 
0.28 (0.369) 
[-0.33 to 0.90] 
-1.79 (<0.001)** 
[-2.64 to -0.94] 
-0.81 (0.008)** 
[-1.40 to -0.21] 
-0.65 (0.019)* 
[-1.20 to -0.10] 
-1.71 (0.026)* 
[-3.21 to -0.21] 
RRMS –Controls -0.19 (0.389) 
[-0.63 to 0.25] 
0.53 (0.032)* 
[0.04 to 1.02] 
-0.65 (0.056)^ 
[-1.32 to 0.01] 
-0.60 (0.013)* 
[-1.07 to -0.13] 
-0.41 (0.058)^ 
[-0.84 to 0.01] 
-0.19 (0.739) 
[-1.38 to 0.98] 
SPMS – CIS -0.50 (0.037)* 
[-0.98 to -0.03] 
0.11 (0.654) 
[-0.40 to 0.64] 
-1.83 (<0.001)** 
[-2.55 to -1.11] 
-0.71 (0.006)** 
[-1.22 to -0.21] 
-0.64 (0.007)** 
[-1.11 to -0.18] 
-1.61 (0.013)* 
[-2.89 to -0.34] 
RRMS – CIS -0.14 (0.383) 
[-0.48 to 0.18] 
0.37 (0.050)* 
[-0.01 to 0.74] 
-0.69 (0.008)** 
[-1.20 to -0.18] 
-0.50 (0.006)** 
[-0.86 to -0.14] 
-0.41 (0.015)* 
[-0.73 to -0.08] 
-0.09 (0.828) 
[-1.00 to 0.80] 
SPMS – RRMS -0.35 (0.136) 
[-0.83 to 0.11] 
-0.25 (0.337) 
[-0.77 to 0.26] 
-1.14 (0.002)** 
[-1.85 to -0.42] 
-0.20 (0.410) 
[-0.71 to 0.29] 
-0.23 (0.307) 
[-0.69 to 0.22] 
-1.51 (0.019)* 
[-2.78 to -0.25] 
 
MS = Multiple sclerosis; RRMS = Relapsing-remitting MS; SPMS = Secondary 
progressive MS; CIS = Clinically isolated syndrome; GM = Grey Matter; NAWM = 
Normal appearing white matter; MTR = Magnetization transfer ratio; PL = Peak location 
PH = Peak height; pu = percentage unit;  
^ Indicates significance level at 0.05 < p ≤ 0.1  
* Indicates significance level at 0.01 < p ≤ 0.05 
** Indicates significance level at p ≤ 0.01 
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Figure 5.1  MTR histogram profiles for the GM and NAWM 
 
 
NB: The average histogram profiles for the GM (left) and NAWM (right) for all 
subgroups: controls (solid line), CIS (dot dash line), RRMS (dashed line) and SPMS 
(dotted line). The peak location is the modal MTR value in pu; the peak height is the 
number of normalised brain units at the modal MTR value. 
 
GM = Grey matter; NAWM = Normal appearing white matter; CIS = Clinically isolated 
syndrome; RRMS = Relapsing remitting multiple sclerosis; SPMS = Secondary 
progressive MS; pu = percentage unit 
 
 
  
 
147
When BPF was also included as covariate (along with age and gender), the only 
significant differences observed were: lower GM PH in SPMS versus (i) CIS [age and 
gender adjusted mean difference (В) = -0.88; p = 0.011] and (ii) RRMS (B = -0.66; p = 
0.036), and lower NAWM PH in SPMS versus RRMS (B = -1.28; p = 0.053). 
 
Univariate correlations of MTR parameters with clinical outcomes and other MRI 
measures are presented in Table 5.3 and Figure 5.2 & Figure 5.3. 
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Table 5.3 Correlations of MTR histogram parameters with T2LL, tissue specific brain 
volumes and disability (MS group only) 
 
T2LL GMF WMF EDSS MSFC MTR histogram 
metrics 
rs (p-value) 
Mean -0.04 (0.780) 0.12 (0.435) 0.43 (0.005)** -0.29 (0.060) 0.30 (0.064) 
PL 0.33 (0.035) * -0.15 (0.350) 0.23 (0.141) -0.12 (0.428) 0.12 (0.448) 
 
 
 
GM 
PH -0.47 (0.002)** 0.71 (<0.001) ** 0.01 (0.921) -0.49 (0.001)** 0.51 (0.001)** 
Mean -0.69 (<0.001)** 0.36 (0.019)* 0.30 (0.051)* -0.27 (0.079) 0.34 (0.037)* 
PL -0.64 (<0.001)** 0.35 (0.024)* 0.20 (0.196) -0.25 (0.107) 0.33 (0.040)* 
 
 
 
NAWM 
PH -0.31 (0.045)* 0.38 (0.013)* -0.002(0.992) -0.25 (0.113) 0.17 (0.287) 
 
GM = Grey matter; NAWM = Normal appearing white matter; MTR = Magnetization 
transfer ratio; PL = Peak location; PH = Peak height; T2LL = T2 lesion load; WMF = WM 
fraction; GMF = GM fraction; EDSS = Expanded disability status scale; MSFC = 
Multiple sclerosis functional score 
rs = Spearman Rank correlation coefficient 
* Indicates significant level at 0.01 < p < 0.05 
** Indicates significant level at p < 0.01 
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Figure 5.2 GM peak height plotted against GMF (top right), T2 lesion load (top left), 
EDSS (bottom right) and MSFC (bottom left) 
 
 
 
GM = Grey matter; GMF = Grey matter fraction; EDSS = Expanded disability status 
scale; MSFC = Multiple sclerosis functional score 
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Figure 5.3  NAWM mean MTR (left) and peak location (right) plotted against Multiple 
Sclerosis Functional Score and T2 lesion load 
 
 
 
NAWM = Normal appearing white matter; MTR = Magnetisation transfer ratio 
 
 
 
 
 
 
  
 
151
Regression models: Table 5.4 
EDSS 
Of the MTR parameters, GM PH was the only independent predictor of disability: there 
was an estimated 76% (p = 0.001) reduction in odds of a patient having greater disability 
per 1SD higher GM PH.  
GM PH remained the only independent predictor, even after adding T2LL and WMF 
measures to the best MTR predictors. Because of the strong correlation between GM PH 
and GMF (rs = 0.71; p < 0.001) their independent contribution could not be estimated in 
the same model (inclusion of both GM PH and GMF in the same model rendered them 
both statistically non-significant); however substituting GM PH with GMF, there was an 
estimated 66% (p = 0.005) reduction in the odds of a patient having higher disability per 
1 SD higher GMF. 
 
MSFC 
Of the MTR parameters, GM PH was the only independent predictor of disability: there 
was a 0.86 (p = 0.001) increase in z-MSFC per 1SD higher GM PH.  
GM PH remained the only independent predictor, even after adding T2LL and WMF to 
the best MTR predictors. Because of the strong correlation between GM PH and GMF (rs 
= 0.71; p < 0.001) their independent contribution could not be estimated in the same 
model; however substituting GM PH with GMF: there was an estimated 0.67 (p < 0.001) 
increase in MSFC per 1SD higher GMF. 
Similar observations were evident when investigating 9HPT and inverted timed walk 
(Table 5.4). None of the MRI parameters predicted PASAT. 
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Table 5.4 Independent predictors in regression models in MS group only  
 
Variables* EDSS 
N = 41 
MSFC 
N = 38 
9HPT 
N = 39 
Inverted timed 
walk N = 37 
PASAT 
N = 39 
MTR 
metrics only 
GM-PH (p = 0.001) 
 
GM-PH (p = 0.001) 
 
GM-PH (p = 0.001) 
 
GM-PH (p < 0.001) 
and gender (p = 
0.018) 
 
None 
GM-PH; 
GMF/WMF; 
T2LL 
Either,  
GM-PH (p = 0.001) 
or GMF (p = 0.005) 
Either,  
GMF (p < 0.001) or  
GM-PH (p = 0.001) 
 
Either,  
GM-PH (p = 0.001) 
or GMF (p = 0.015) 
and T2LL (p =0.007) 
 
Either,  
GMF (p < 0.001) or 
GM-PH and gender (p 
= 0.041) 
 
None 
 
 
* Age and gender were used as covariates on all models; (N = number of patients shown); 
GM = Grey matter; GMF = GM fraction; WMF = White matter fraction; PH = Peak 
height; MTR = Magnetization transfer ratio; T2LL = T2-weighted lesion load; EDSS = 
Expanded disability status scale; MSFC = Multiple Sclerosis functional composite score 
9HPT = 9 Hole peg test; PASAT = Paced Auditory Serial Addition Test  
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Discussion 
This study builds on work presented in Chapter 4 with this cohort in two ways: it 
characterises intrinsic tissue specific changes, as measured by MTR, in a group of people 
with long and homogeneous disease duration not markedly confounded by the potential 
effects of disease modifying treatments, and it explores the relative contribution of GM 
and WM MTR, and atrophy, to clinical outcomes in MS. The main observations were 
that: (i) MTR abnormalities can be found in GM and NAWM; (ii) both are associated 
with clinical outcomes, although GM more so than NAWM; (iii) GM MTR PH and GM 
atrophy (GMF) measures explain similar degrees of variability in disability scores; and 
(iv) such measures are more clinically relevant in the longer term than T2LL estimates. 
 
MTR parameters (especially PH in GM and less so, mean MTR and PL in NAWM) were 
generally lower the more clinically advanced a patient’s MS had become following a 
consistent stepwise pattern: they were lower in SPMS than in RRMS, and lower in 
RRMS than in healthy controls and those remaining classified as CIS, but there were no 
differences between CIS and healthy controls. These results suggest that MTR 
abnormalities in GM and NAWM – but more so in GM – may mark on-going disease 
activity, rather than reflecting any residual effects of a CIS.  
 
Volume normalised MTR histogram measures are principally influenced by three factors: 
the average MTR values within a tissue, tissue variability, and skew. This means for two 
tissues with similar mean MTR, an increase in tissue heterogeneity will lead to a 
reduction in PH. For tissues with different mean MTR values, an increase in tissue 
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heterogeneity will tend to mask such differences. It is therefore worth considering a given 
MTR histogram parameter in the context of its standard deviation. The PL relative to the 
mean MTR provides some insight into the skew of the histogram. A PL lower than the 
mean MTR, suggests the histogram is skewed towards higher values. 
 
In this study, we see that the main disease effects in GM appear to be an increase in tissue 
heterogeneity, with greater skew towards lower MTR values (PL significantly increases, 
while mean MTR marginally reduces) when compared to healthy controls. In the NAWM 
tissue heterogeneity also increases, but not to a degree that this masks a reduction of the 
mean MTR values (as well as reduction in concurrent PL). This differential disease effect 
may in part be due to the much greater ability using current MRI techniques to detect 
(and therefore exclude) WM lesions. Hence, the GM is more likely to contain 
demyelinated lesions than the NAWM, and so be more heterogeneous. Further, given its 
relatively small myelin content (compared to the WM) a larger proportional reduction in 
GM myelination is probably required to be detected using MTR. In summary, it is 
plausible that the GM MTR findings reflect a greater mixture of lesional and non-lesional  
cortex – the later constituting the majority of GM tissue – with the results being a 
combination of reduced mean MTR and increased PL, whereas NAWM MTR findings 
reflect a more subtle non-lesional diffuse abnormalities (e.g. a combination of microglial 
activation (Kutzelnigg et al., 2005), inflammation, demyelination, astrogliosis and axonal 
loss) with reductions in both the mean and PL.  
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The study presented in Chapter 4 on a larger subset of the same cohort of patients, 
showed that GM but not WM atrophy measurements correlated with disability. However, 
in this study the association between MTR measures and clinical outcomes appears to be 
less tissue specific than for atrophy. Whilst GM MTR was more closely related to clinical 
outcomes, NAWM MTR parameters were also correlated with clinical scores: GMF, but 
not WMF correlated with clinical outcomes. This disparity may in part reflect differences 
in the nature of GM and WM pathology, in particular noting that WM lesions appear 
more inflammatory than those in GM (Bo et al., 2003). If this holds true for normal-
appearing tissues, we may expect that inflammation associated oedema will tend to 
compensate for atrophy associated with cell loss more in the WM more than GM, while 
simultaneously diluting cell densities more in the WM than GM, which in turn may 
influence the strength of associations between tissue specific MRI measures with clinical 
outcomes.  
 
A recent histopathological study of an experimental model of MS has suggested that 
cortical demyelination and atrophy may not be closely linked (Pomeroy et al., 2008). In 
contrast in this data, it is shown that GMF and GM MTR PH were strongly correlated (rs 
= 0.71). Whilst the above discrepancy may represent known difficulties to translating 
findings from animal models of MS into human disease and vice-versa, if we assume that 
the substrates of MTR change in the GM are similar to those in the WM (i.e. weighted to 
a degree towards myelination, but not purely so (Schmierer et al., 2004)), these findings 
would suggest a link between GM demyelination and atrophy; if not, it would suggest 
that MTR changes in the GM, compared with the WM, at least in long-term MS, are less 
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weighted towards demyelination, and perhaps share another common substrate such as 
neuronal and or axonal loss. 
 
Whilst a correlation of brain atrophy and MTR has been evident in previous studies 
looking at early RRMS patients (Davies et al., 2005; Phillips et al., 1998), MTR 
especially of the GM, appeared to be independent of brain atrophy when distinguishing 
MS patients from controls (Davies et al., 2004; Fernando et al., 2005), this was not the 
case in this study. Given that disease associated atrophy is generally more marked, and 
spans a greater range, in the present cohort (disease duration ~20 years) compared with 
people with shorter disease duration, this observation may be the result of greater power 
to detect correlations rather than true biological differences. It may also relate to partial 
volume effects, which tend to increase at tissue volumes decrease. Whilst measures were 
taken to limit this, we cannot entirely discount this possibility. However, it may also 
represent a true pathological link between intrinsic tissue damage and atrophy with 
connected features including demyelinating lesions and neuronal loss. 
 
Correlation between T2LL and NAWM MTR was stronger than with GM MTR. 
However, at best such correlations accounted for about 50% of shared variability, 
suggesting that global WM and more particularly GM MTR changes are at least partly 
independent of focal WM lesion formation. In addition, GM PH was a better predictor of 
clinical outcomes than T2LL, reinforcing the conclusion from previous work presented in 
Chapter 4 that GM pathology is an important determinant of disability in MS.  
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When considering these results, in addition to those noted above, several other limitations 
should be kept in mind. Firstly, studies have reported mean GM MTR (Davies et al., 
2004)  and the others have reported PH (Agosta et al., 2006) as better correlated with 
disability, but differences in MTR sequences across different scanners and centres 
(Rovaris et al., 2008), and variation in processing methodologies (Fernando et al., 2005; 
Filippi, 1999; van Buchem et al., 1999), may influence the relative sensitivity of the 
various MTR metrics to pathology. Secondly the cohort of patients presented here has a 
bias towards those with lower disability (benign-MS) of all who were seen at 20 years (it 
was not possible to scan some of the more disabled patients), potentially limiting the 
scope to fully investigate associations between MRI measures and disability. Thirdly, 
current image techniques have limited ability to detect cortical lesions (Geurts et al., 
2005; Geurts et al., 2008); thus there is uncertainty to what extend such lesions account 
for the GM MTR change seen. Future MR hardware (e.g. high field scanners at 3 Tesla 
and above) and sequence developments (e.g. double inversion recovery, phase sensitive 
inversion recovery) should focus on better detection of GM lesions (Geurts et al., 2005; 
Nelson et al., 2007). Fourthly, no assumption can be made about the longitudinal changes 
in MTR and atrophy in predicting disability. While a subgroup of the patients had similar 
sequences acquired at 14 year follow up, a major scanner hardware upgrade, rendered it 
difficult to directly compare measurements from earlier scanning with that obtained at 20 
years. 
 
Not withstanding these limitations, this study shows that GM damage – as marked by 
MTR changes – is related to disability in MS, and is a better predictor of clinical 
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outcomes than NAWM MTR, WM lesion load or WM atrophy in patients with 
longstanding MS. 
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Chapter 6 
 
Early brain white matter lesion formation predicts long-term grey more than white 
matter atrophy in relapse onset multiple sclerosis 
 
Introduction 
Magnetic resonance imaging white matter (WM) lesions (T2LL) are usually a 
conspicuous feature early in the clinical course of relapse-onset multiple sclerosis (MS), 
but whilst they have a role in predicting who will convert to clinically definite MS 
following a clinically isolated syndrome (CIS) (Polman et al., 2005; Swanton et al., 2007) 
they predict the long-term disability only modestly (Brex et al., 2002). In contrast, brain 
atrophy although evident from disease onset (Brex et al., 2000; Dalton et al., 2004) , is 
more readily apparent in the later clinical stages of MS (Dalton et al., 2006; Fisher et al., 
2008). Further, there is growing evidence suggesting that in the long-term in MS there is 
more GM than WM atrophy, and that GM atrophy is more closely related to disability 
(Fisher et al., 2008; Pirko et al., 2007). 
 
The long-term relationship between changes in T2LL with brain atrophy is uncertain. A 
previous study involving people 14 years after first presentation with a CIS, showed that 
early rather than later changes in WM T2LL predicted whole brain atrophy at 14 years, 
but the tissue specificity of the atrophy measures in this association was not investigated 
(Chard et al., 2003). Cross-sectional work has hinted at more consistent associations 
between GM rather than WM atrophy and T2LL accrual, and so building on this previous 
study, using recently acquired 20 year follow up data in the same cohort, I sought to 
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confirm these previous findings, and in addition characterize the relationship between 
lesion accrual and tissue specific (GM and WM) atrophy.  
 
Methods 
Subjects 
The patients included in this study are part of a larger cohort of patients seen from their 
first presentation with a CIS and followed up approximately every 5 years for 20 years 
described in details in Chapters 3 and 4.  Seventy-five out of 107 patients seen at 20 years 
had the clinical and MRI data acquired. Only 73 were included in this study as one did 
not complete the full scanning protocol, and the other developed cerebrovascular disease 
in addition to MS. Forty patients had T2LL collected at all data time-points available. 
Twenty-five healthy controls were imaged in parallel with the CIS cohort’s 20 year 
follow up. 
 
The diagnosis of clinically definite MS was made on the clinical grounds (Poser et al., 
1983) and the course of MS was based on the Lublin et al criteria (Lublin & Reingold, 
1996). Disability in patients was measured by using Expanded Disability Status Scale 
(EDSS) (Kurtzke, 1983). The study was approved by the National Hospital for Neurology 
and Neurosurgery and Institute of Neurology Joint Research Ethics Committee. All study 
participants gave written informed consent. 
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Image Acquisitions and Processing  
Baseline and 5 year MRI scans were obtained on a 0.5 Tesla scanner (Picker, Cleveland) 
and on a 1.5 Tesla GE Signa Echospeed scanner (General Electric Signa, Milwaukee) at 
10, 14 and 20 years. Contiguous, axial slices covering the whole brain were obtained at 
all visits. In a minority of early baseline scans (1984/1985) slice thickness was 10 mm; it 
was 5 mm for all subsequent scans. At 20 years, the following sequences were acquired: 
i) 2D dual-echo proton density (TE 17ms) and T2 (TE 102ms) weighted fast SE [TR 
2000 ms; 28 × 5 mm slices; field of view 24 × 18 cm2; in-plane resolution of 1.1 mm];  ii) 
3D axial T1-weighted inversion-prepared fast spoiled gradient recall  [TR 10.9 ms; TE 
4.2 ms; inversion time 450 ms; 124 × 1.5 mm slices; imaging matrix 256 × 160, 
interpolated to a final in-plane resolution of 1.1 mm; flip angle 20º]. 
 
Using a previously described technique (Sailer et al., 1999), T2LL were obtained using 
the proton density-weighted scans (short echo) of sequence (i) and 3D T1-weighted lesion 
load was computed from sequence (ii). WM, GM and brain parenchymal fraction (WMF, 
GMF and BPF) were obtained from sequence (ii) using SPM2 (Wellcome Department of 
Cognitive Neurology, London, UK), corrected for lesion misclassification as GM (Chard 
et al., 2002). 
 
Statistical Analyses 
The data were analyzed using Stata 9.2 (Stata Corporation, College Station, TX, USA). 
Statistical significance was taken at p<0.05. 
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Longitudinal linear mixed models were used to assess the rate of T2LL accrual, the 
confounding effect of slice thickness on T2LL and rate of growth, and the associations of 
rate of T2LL growth and tissue specific atrophy. T2LL was used as a response variable 
with time, patient group (CIS or MS at 20 year follow up), GMF and WMF as covariates 
with additional interactions with time where appropriate, using all available data time-
points for T2LL. The models were run on the all patients, and on the subset of patients 
who had T2LL data available for all time-points. To assess for non-linearity, in addition 
to the linear term, a quadratic term was also fitted. GMF and WMF were expressed as 
standardized values for convenience of interpretation. 
 
Results 
The demographics of all the subjects are shown on Table 6.1. The 20 year GM and WM 
fractional volumes were lower in MS patients compared with controls (p < 0.001 and p = 
0.01 respectively).  There was no evidence of non-linear lesion load growth in either 
group and there was no evidence of difference in linearity between the two groups (p = 
0.352). Slice thickness did not significantly influence estimated lesion volumes or the 
gradient of lesion growth.  
 
Lesion volume at baseline was lower by 1051.4mm3 (p = 0.044) for every additional 1 
SD higher GMF at 20 years for all patients, 26.3mm3 lower per 1 SD higher GMF (p = 
0.984) for those patients who did not develop MS, and 1419.1mm3 (p = 0.035) for those 
who did. However, the difference in association between MS and non-MS was not 
significant (p = 0.316).  For every 1SD greater 20 year GMF, the annual rate of lesion 
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growth decreased by 526.5mm3; (p < 0.001) for all patients; 533.2mm3; (p < 0.001) for 
MS patients only and by 87.3mm3 (p = 0.517) for those who remained CIS (see Figure 
6.1 and 6.2).  
 
Lesion volume at baseline was lower by 1895.9mm3; p <0.001 for every 1 SD higher 
WMF at 20 years. The association was different in those who developed MS compared 
with those who remained CIS (p = 0.018): in the group who remained CIS, the baseline 
lesion volume was lower by 493.8 mm3; p = 0.917, per additional SD WMF at 20 years, 
while in the MS group it was lower by 2621.2mm3; (p< 0.001). The overall rate of lesion 
growth was not associated with WMF at 20 years in either group of patients. 
 
Restricting the analysis to the MS patients (N = 27) in whom all the T2LL at all-time-
points was available, change in T2LL over the first 5 years was more closely related to 
GMF than subsequent T2LL changes: 1 SD higher T2LL in years 0-5 predicting 1.3 SD 
lower GMF (p < 0.001) versus 1 SD higher T2LL in years 5-20 predicting 0.5 SD lower 
GMF (p < 0.001). Only the changes in T2LL over the first 5 years predicted WMF at 20 
years: 1 SD higher lesion growth predicted 1.03 SD lower WMF (p = 0.01). 
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Table 6.1  Demographics of all subjects scanned at 20 years 
 
Demographics All patients Patients with all 
T2LL available 
Controls 
Subjects (all) 
    CDMS 
    RRMS 
73*$ 
67 
39 
40 
27 
21 
25 
--- 
--- 
Female : Male 49 : 24 26 : 14 14 : 11 
Mean follow-up 
(years) (range) 
20 (18-27) 19.7 (18-26) --- 
Mean age (SD) 51.4 (7.2) 50.8 (6.5) 41.7 (7.7) 
Median (range) EDSS 
  All patients 
  CDMS only 
 
2.5 (0-8) 
3.25 (1-8) 
 
2.5 (0-8) 
3.0 (1-8) 
 
--- 
Mean (SD) 
  GMF 
  WMF 
 
0.49 (0.03) 
0.28 (0.01) 
 
0.49 (0.03) 
0.28 (0.01) 
 
0.51 (0.01) 
0.29 (0.01) 
 
MS = Multiple Sclerosis; CDMS = Clinically definite MS; GMF = Grey matter fraction; 
WMF = White matter fraction; T2LL = T2-weighted WM lesion load 
* 107 patients were seen at 20 years. The demographics of the whole cohort are reported 
on chapter 3.  
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$ 2 other patients were excluded from the analysis – one developed cerebrovascular 
disease in addition to MS and the other patient did not complete the full MRI scanning 
protocol 
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Figure 6.1 Predicted rate of lesion growth by the 20th centile GMF at 20 years – all 
patients (lesion growth expressed in cm3) 
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Figure 6.2  Predicted rate of lesion growth by 20 year GMF centiles – MS patients only 
(lesion growth expressed in cm3) 
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Discussion 
 
The main findings of this study were: i) baseline T2LL predicts long-term WM atrophy 
more than GM atrophy; iii) subsequent T2 lesion accrual, particularly in the first 5 years, 
is a better predictor of long-term GM rather than WM atrophy; iv) the changes in T2LL 
only partially explain the brain atrophy at 20 years. 
 
Given that the atrophy was only measured at 20 year follow up time-point, one cannot 
determine when the observed atrophy occurred, or whether there is a  temporal difference 
in the evolution of lesion load and atrophy. It is known from other studies that early 
increasing GM atrophy occurs in MS (Chard et al., 2002; Dalton et al., 2004). 
Nevertheless, there are several possible explanations why there may be a delay between 
lesion formation and atrophy. Firstly, slowly evolving tract-mediated neurodegeneration 
may occur following the occurrence of an acute focal demyelinating lesion; for example 
thinning of the retinal nerve fibre layer on optical coherence tomography is not fully 
evident until ~6 months after an epoisode of optic neuritis (Henderson et al., 2010). 
Secondly, both lesion formation and tissue atrophy may be related to the same underlying 
process, but occur with different latencies. Thirdly, tissue atrophy may occur at the time 
of lesion formation but be masked by inflammation associated oedema and cellular 
infiltration, and subsequently only become manifest as this settles. 
 
Why should the longitudinal increase in lesion load relate more to later GM (rather than 
than WM) atrophy? One possibility is that GM tissue is more vulnerable to inflammatory 
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lesion-mediated neurodegeneration. Neurons and their projections make up more of the 
GM than WM (Chard & Miller, 2009), so even if loss of neurons and axons are equally 
related to lesion load formation in both WM and GM, correlations with WM lesion loads 
are more likely to be found, or appear to be stronger, with GM rather than WM atrophy. 
Another possibility is differential inflammatory activity of WM lesions compensating for 
volume loss in WM more than GM with the GM lesions being less inflammatory 
(Peterson et al., 2001).  
 
The explanation of a stronger relationship between baseline T2LL and later WM (rather 
than GM) atrophy is uncertain. It may be that WM atrophy is a marker of a very early 
process in the disease, whereas GM atrophy is more influenced by events taking place 
throughout the disease course. Previous serial studies in early RRMS support this concept 
in reporting early but stable WM atrophy with increasing GM atrophy (Chard et al., 2004; 
Tiberio et al., 2005).  
 
In addition to those study limitations noted above, two others are particularly worth 
mention: we did not find a significant confounding effect of the slice thickness on lesion 
volumes and rate of lesion growth, but could not assess the reproducibility of early versus 
later measures, as such may be underestimating the strength of the association between 
early lesion formation and later atrophy; the segmentation of the brain tissues using SPM 
(as with other methods) is imperfect, and in the case of SPM tends to misclassify the T1 
hypointense lesions as GM – a lesion mask was used to correct for this, but small residual 
errors may remain.  
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In conclusion, in this study we found that in the longer-term following a CIS suggestive 
of MS, the rate of lesion growth is related more to later GM than WM atrophy and early 
more so than later accumulation of WM lesions predicts brain atrophy. 
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PART IV 
 
CONCLUSIONS 
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Chapter VII 
 
SUMMARY & CONCLUSIONS 
 
 
The aim of this thesis was to assess the role of MRI as a predictor of disability in relapse-
onset MS patients. I was fortunate enough to be able to work with a rather unique cohort 
of patients who were seen from the disease onset with a clinically isolated syndrome and 
followed up prospectively with clinical and MRI data every five years up to 20 years. The 
data gathered is unique not only because it is the longest MRI study of MS patients but 
also because it has given me a unique cohort of patients with different subtypes of MS 
who also have a rather homogenous disease duration as well as age of disease onset. 
Furthermore, this is a drug naive cohort of patients as only very few patients were on 
disease modifying treatment, hence the observed relationship between the MRI and the 
clinical disability is representative of the “true natural” relationship of MRI and disability 
in MS. 
 
So what does this data add to what had already been known about this relationship? Are 
the findings confirmatory to the overwhelming number of MRI studies done in MS? Does 
this data accept or reject the concept of the MRI paradox in MS? What are the service 
and the novelty that this work offers to research in MS and the MS community as a whole 
and where does the future of imaging lie in MS? 
 
The main findings from this work are: 
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i. CIS patients with an abnormal MRI scan at presentation are more 
likely to convert to clinically definite MS than those with a normal 
MRI scan (82% versus 21%). 
ii. MS patients exhibit a wide spectrum disability 20 years after disease 
onset. 
iii. MRI lesions on the baseline scan provide limited prediction for long 
term disability. 
iv. There is moderate correlation of T2 lesion volume at all time point 
with disability at 20 years. 
v. Concurrent correlation between T2 lesion volume and EDSS change is 
mainly in the first 5 years and weak or absent at later intervals. 
vi. Lesion load continues to increase for at least 20 years in relapse onset 
MS patients and it is higher in those who develop SPMS than those 
who retain a relapsing remitting course. 
vii. In MS patient with a long and homogenous disease duration there is 
more GM damage than WM damage as measured by atrophy and 
MTR. 
viii. GM damage reflects disease subtype and disability more so than WM 
damage, independent of disease duration or age.  
ix. Earlier more so than later lesion accumulation is related to subsequent 
GM and WM atrophy. 
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I believe the data from this work has direct implications in the care of MS patients 
especially as it offers help in being able to counsel the patients regarding their chances of 
converting to MS after their first presentation with a CIS. The baseline MRI scan offers 
the strongest predictive value to conversion to MS independent of the clinical 
presentation. MRI studies had shown that conventional MRI measures such as lesion 
volumes modestly predict disability in MS on short and medium follow up studies. Data 
from this work robustly confirms these findings but furthermore, sheds new light in 
establishing that the lesion volumes continue to increase and are on average three times 
higher in SPMS than RRMS. 
 
It was this modest predictive value of lesion load for disability in MS that made me look 
at other MR measures of tissue specific involvement. And although the GM involvement 
has been known for years, hence the observed differences between MS and controls was 
not a surprise, this data quite significantly showed that not only there is more GM atrophy 
than WM atrophy in MS patients with a long disease duration but also that GM atrophy is 
more clinically relevant to long term disability than WM atrophy or indeed WM lesions. 
The MTR data also suggest the importance of GM pathology for long term disability. 
 
This work was not devoid of limitations which are discussed in detail in each relevant 
result chapter. Nevertheless despite these limitations and taking into account the 
shortcomings of MRI technology, imperfections of the disability scales which are 
currently available to us and the “hiccups” of the analysis techniques used, I believe that 
this data has shed some light in our understanding of MS. In particular, it has emphasised 
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that MS is a complex generalized disease where the WM lesions are only a component – 
albeit a clinically relevant one - of the pathology and that GM (along with so-called 
NAWM and the spinal cord) pathology also plays an important role.  Overall, my work 
has illuminated the so-called clinical-MRI paradox  in MS by identifying in vivo, through 
long term follow up and use of quantitative and tissue-sepcific measures, key aspects of 
MS pathology. 
 
In future, further development of pathologically specific MRI hardware (e.g., high field 
scanners) and quantitative measures including spectroscopy, diffusion tensor imaging, 
volumetric measurement, magnetization transfer ratio and other techniques for 
assessment of the GM involvement, along with improvement of the clinical outcome 
measures and more longitudinal studies, challenging though they might be, will clarify 
the  role of MRI as a predictive tool in MS. This will be extremely important as the 
emergence of new disease modifying treatment requires robust surrogate markers to 
assess their efficacy. 
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